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Serological tests are conducted to assess humoral response against viral protein 
antigens, to assess viral exposure and protection from pathogens. The rapid development 
and modularity of serological assays have proven critical to managing the current SARS-
CoV-2 pandemic. The receptor binding domain of SARS-CoV-2 is within the trimeric 
Spike protein and serves as a highly immunogenic target for potentially neutralizing 
antibodies. Current receptor binding domain serological assays use recombinant 
monomers or dimers of the receptor binding domain. The receptor binding domain is 
presented to the immune system natively in the context of the Spike protein trimer. 
Therefore, a recombinant trimeric receptor binding domain may be predictive of 
protection and improve antibody binding. For this thesis, using the trimerization domain 
from Bacteriophage T4 Fibritin, called Foldon, fused to the receptor binding domain, a 
novel antigen was produced. The antigen was expressed in and extracted from Nicotiana 
benthamiana plants, purified through immobilized metal affinity FPLC, and used to 
develop a serological ELISA. The antigen was tested with hospitalized (n=46), non-
hospitalized (n=36), and negative (n=46) patient sera sample lots and batch 
reproducibility was examined. From these studies, it was concluded that this trimeric 
antigen can be consistently expressed, extracted, and purified and can be used to reliably 
detect responses to SARS-CoV-2 in sera. Additionally, fusion of the Foldon trimerization 
domain to trimeric viral proteins serves as a platform for the development of plant 
produced viral antigens to better detect host response. 
 





RBD-foldon = Receptor Binding Domain from Spike Protein S1 Subunit of SARS-CoV-
2 fused to the C-terminal trimerization domain of bacteriophage T4 fibritin through a 
glycine-serine linker, called “Foldon”, fused to a C-terminal 6x histidine tag. 
Spike = The spike protein (S) of SARS-CoV-2, made up of two subunits, S1 and S2 
Zoonotic = Descriptor for a pathogen that has jumped from a non-human animal to 
humans. 
ELISA = Enzyme Linked Immuno-Sorbent Assay 
TMV = Tobacco Mosaic Virus 
FPLC = Fast Protein Liquid Chromatography 
HPLC = High Performance Liquid Chromatography 
SEC = Size Exclusion Chromatography 
IMAC = Immobilized Metal Affinity Chromatography 
UF/DF = Ultrafiltration/Diafiltration 
PRNT50 = Quantitative value obtained from Plaque Reduction Neutralization Assay; 
Inverse of the highest sera dilution producing 50% viral plaque neutralization. 
EC50 = Half maximal effective concentration; refers to the binding of a molecule to a 
receptor. 
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The first four cases of Coronavirus Disease 2019 (COVID-19) were reported on 
December 29th of 2019 in Wuhan, China. The symptoms were initially reported as 
“pneumonia of unknown etiology” (Q. Li et al., 2020). These symptoms were then 
identified to be a result of a newly identified beta-coronavirus. The World Health 
Organization initially called this the 2019-novel Coronavirus, and it was later named 
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by the Coronavirus 
Study Group (CSG) (Guo et al., 2020) as it has significant genetic similarity to Severe 
Acute Respiratory Syndrome Coronavirus (SARS-CoV) of 2003 (Coronaviridae Study 
Group of the International Committee on Taxonomy of, 2020). Phylogenetic analysis 
places SARS-CoV-2 within the family of coronaviridae and genus of beta-coronavirus, 
sharing phylogenetic similarity to the two other epidemics, beta-coronaviruses SARS-
CoV and Middle East Respiratory Syndrome (MERS-CoV) (Coronaviridae Study Group 
of the International Committee on Taxonomy of, 2020). SARS-CoV-2 is more infectious 
than SARS-CoV and MERS-CoV, and, as of February 27, 2021, there have been over 
113 million confirmed cases of and 2.5 million deaths from COVID-19 worldwide 
(WHO, 2021).  
 There are four subgroups of coronaviruses: alpha-, beta-, gamma-, and delta-
coronaviruses. Alpha- and Beta- coronaviruses infect mammals, while gamma- and delta-
coronavirus infect birds. There have been seven human coronaviruses identified: alpha-
coronaviruses HCoV-229E and -NL63 and beta-coronaviruses HCoV-OC43, -HKU1, 
SARS-CoV, MERS-CoV, and the most recent SARS-CoV-2 (Chaung, Chan, Pada, & 




Tambyah, 2020). The HCoV-229E, -NL63, -OC43, and -HKU1 are endemic and are 
responsible for mild to moderate upper respiratory tract irritation, making up 15-30% of 
common cold cases in adults. Contrarily, SARS-CoV, MERS-CoV, and SARS-CoV-2 are 
zoonotic epidemic pathogens (Chaung et al., 2020).  
SARS-CoV-2, ranging from 65-125nm in diameter, is a beta-coronavirus, 
containing positive sense, single-stranded RNA. Its RNA length ranges from 26 to 32 
kilobases (Shereen, Khan, Kazmi, Bashir, & Siddique, 2020). SARS-CoV-2 expresses 
~20 total nonstructural and structural proteins. The four major structural proteins it 
expresses are: Envelope protein, within the viral membrane; Nucleocapsid protein, within 
the viral envelope; Spike protein, on the membrane of the viral particle; and Membrane 
protein, to which the other structural proteins bind and anchor to (Astuti & Ysrafil, 2020). 
Spike protein is trimeric, and each monomer is cleaved into subunits S1 and S2, 
facilitating viral entry into a cell. The Receptor Binding Domain, or RBD, is present 
within the S1 subunit of Spike protein. RBD (Astuti & Ysrafil, 2020) is normally 
presented to the human immune system in the context of the Spike trimer and could 
provide immunity/protection from SARS-CoV-2 due to its high immunogenicity (Zost et 
al., 2020). Testing for the immune response to viral exposure is useful in predicting 
protection and potential vaccine effectiveness over time. However, testing for exposure to 
and protection from COVID-19 contains a margin of error. This margin of error includes 
the possibility of false negative and false positive responses as a result of varying assay 
sensitivities and specificities. Due to the immediate need for testing of exposure and 
protection as a result of the spike in cases, a number of antigen testing strategies have 




been developed in a short period of time. Although the results of these tests are mostly 
sufficient, there is a degree of error, and therefore a need to improve them.  
Currently, serological diagnostics use SARS-CoV-2 RBD, Spike Protein, or 
Nucleocapsid protein. Serological diagnostics using SARS-CoV-2 RBD or Spike Protein 
can predict exposure and protection, whereas those using Nucleocapsid protein can only 
predict exposure. The most reliable of these serological diagnostics to detect exposure are 
those using Nucleocapsid or Spike protein as an antigen (Coste, Jaton, Papadimitriou-
Olivgeris, Greub, & Croxatto, 2021). Nucleocapsid has a high rate of false positives as it 
is highly conserved amongst coronaviruses. Spike protein is less conserved and has 
several glycosylated sites to which more specific antibodies are produced (Meyer, 
Drosten, & Muller, 2014). Tests using recombinant non-glycosylated spike protein have 
an increased level of false negatives (Coste et al., 2021). As for predicting protection, the 
most reliable of these serological diagnostics are those with RBD as an antigen 
(Premkumar et al., 2020), but there are still potential false positives and false negatives 
(Tai, Zhang, He, Jiang, & Du, 2020). RBD is highly immunogenic and is exposed on the 
surface of viral particles during binding to the receptor, human Angiotensin Converting 
Enzyme 2 (hACE2), making it an accessible target for neutralizing antibodies (Zost et al., 
2020).  
Conversely, Nucleocapsid protein is encapsulated within the viral envelope, and 
when presented with a viral particle, Nucleocapsid-specific antibodies would not have 
access to Nucleocapsid protein, being hindered by the viral membrane, and therefore 
would not be able to exhibit any neutralizing activity. For the scope of this study, 




predicting protection from SARS-CoV-2 is of primary importance. Current serological 
diagnostics that use RBD as a target antigen use a monomeric or dimeric RBD, while 
none use a trimeric RBD (Bouwman et al., 2021). Given that RBD is an epitope of the 
SARS-CoV-2 Spike protein that is presented to the host as a trimer (Yu et al., 2020), a 
serological test using an RBD that is reflective of that in live virus may correlate better 
with neutralization than currently used antigens. For this study, a fusion protein was 
constructed, produced, and characterized. This protein, named “RBD-foldon,” fuses the 
SARS-CoV-2 RBD with the c-terminal trimerization domain of Fibritin from 
Bacteriophage T4, “Foldon”. The development of RBD-foldon will be used as a platform 
for viral diagnostics and that may be predictive of viral protection.  
Aim 1 will establish a reproducible purification method for plant-expressed RBD-
foldon. Nicotiana benthamiana plants will be transfected with RBD-foldon viral 
expression vector to express RBD-foldon through the apoplasts. RBD-foldon protein will 
then be extracted from transfected plants and purified through IMAC FPLC and 
concentrated by UF/DF. The final purity of plant-produced RBD-foldon will be verified 
through SDS PAGE and its identity confirmed with Western Blotting.  
Aim 2 will establish a serological assay using RBD-foldon as the target antigen. 
Serological testing using a plate-based ELISA method allows for the level of immune 
response to be assessed following an active infection. Plant-produced RBD-foldon in 
Aim 1 will allow for the optimization of coating concentration of RBD-foldon for 
ELISAs. Following this, ELISAs will be conducted to assess COVID positive, pre-




COVID negative, and pre-COVID HIV positive human sera IgG/IgA/IgM responses to 
RBD-foldon.  
Aim 3 will assess the efficacy of RBD-foldon as an antigen for sera 
immunoglobulins, examining the correlation between immunoglobulin binding of RBD-
foldon and viral neutralization. ROC curves will be constructed to assess the sensitivity 
and specificity of the assay, and antibody titrations will be conducted for each sera 
sample. The antibody endpoint titers will then be compared to PRNT50 data for each 
corresponding sera sample to analyze the correlation between the two variables.   
The proposed studies will establish a new RBD antigen that will provide better 
insight into antibody binding of SARS-CoV-2. The innovative antigen will enhance 
serological assay detection of anti-RBD antibodies and provide a platform for developing 
new viral antigens to better understand viral function and host immune response. 
 Research has been conducted and published that provides the basis for developing 
an RBD antigen that is reflective of the conformation of RBD presented to the human 
immune system in a SARS-CoV-2 infection. 
The complete genome of SARS-CoV-2 was first sequenced by Lu, Zhao, et al. 
They obtained samples from nine inpatients with viral pneumonia, eight of which had 
been to the market in the period in which the outbreak may have originated in Wuhan, 
China, the ninth having stayed in a hotel near the market. Each patient tested negative for 
all common respiratory pathogens. Eight complete genome and two partial genome 
sequences of SARS-CoV-2 were obtained from the nine samples. Lu, Zhao, et al. 
compared sequence homology between the SARS-CoV-2 sequence, two SARS-like bat 




coronavirus (BatCoV-ZC45 and BatCoV-ZXC21), SARS-CoV, and MERS-CoV. The 
SARS-CoV-2 sequence shared 88% sequence homology with both SARS-like bat 
coronaviruses, suggesting that bats may have been the intermediate that enabled the virus 
to transition from animals to infecting humans (Lu et al., 2020). The sequence homology 
with SARS-CoV and MERS-CoV were 79% and 50% respectively. When comparing the 
predicted coding regions of each known coronavirus sequence to those of SARS-CoV-2, 
Lu, Zhao, et al. found that SARS-CoV-2 had a comparable genomic organization to 
BatCoV-ZC45, BatCoV-ZXC21, and SARS-CoV. They also found that, except for minor 
insertions or deletions, the lengths of most of the encoded proteins were similar. Another 
study by Zhou et al. found that SARS-CoV-2 showed high genome sequence homology 
to BatCoV-RaTG13 of 96.2%, suggesting that BatCoV-RaTG13 is the closest relative to 
SARS-CoV-2 (Zhou et al., 2020a, 2020b).  
The spike protein (S) of coronaviruses cleaves into two subunits: an S1 domain, 
containing a receptor binding domain (RBD), and an S2 domain, which is responsible for 
membrane fusion (Figure 1). After examining the amino acid sequence of the S domain, 
SARS-CoV-2 was determined to have 50 conserved amino acids in S1 with SARS-CoV 
(Lu et al., 2020). This homology suggests a similar receptor binding mechanism between 
SARS-CoV and SARS-CoV-2. Complementarily, in a study conducted by Tang, et al., it 
was determined the fusion protein (FP) in the S2 domain of SARS-CoV-2 has 93% 
sequence homology with that of SARS-CoV, suggesting a similar membrane fusion 
mechanism between the two coronaviruses (Tang, Bidon, Jaimes, Whittaker, & Daniel, 
2020). In the same study, Tang et al. also state that within the S1 subunit of coronavirus 




spike protein are two subdomains which can both serve as the Receptor Binding Domain 
(RBD), interacting directly with the receptor. These subdomains are called the N-terminal 
domain (NTD) and the C-terminal domain (CTD) (Tang et al., 2020). The CTD serves as 
the Receptor Binding Domain in SARS-CoV-2, SARS-CoV, and MERS-CoV(Peng et al., 
2011; Tang et al., 2020; Zost et al., 2020). The CTD of both SARS-CoV and SARS-CoV-
2 bind to angiotensin converting enzyme 2 (ACE2), while the CTD of MERS-CoV binds 
to dipeptidyl peptidase 4 (DPP4). Determined by Peng et al., the NTD facilitates binding 
of sugar-receptors, whereas the CTD facilitates binding of protein-type receptors (Peng et 
al., 2011); hence, the CTD binding with the protein-type receptors ACE2 and DPP4.  
 
 
FIGURE 1 – SARS-CoV-2 Spike Protein Amino Acid Sequence for Wuhan-Hu-1 Isolate (Purple: Signal Peptide, 
Green: S1 Subunit, Red: Receptor Binding Domain, Blue: Furin Cleavage Site, Orange: S2 Subunit) 
 
In a study conducted by Yan et al., they investigated the structural basis for the 
recognition of SARS-CoV-2 by human ACE2 (Yan et al., 2020). ACE2 is prevalent in 
humans in the lung and intestine epithelium, and less prevalent throughout the venous 




and arterial endothelium and arterial muscle cells throughout the body (Hamming et al., 
2004). ACE2 is responsible for mediating the maturation of the peptide hormone 
angiotensin, which is the end product in the renin-angiotensin system of the kidney, 
responsible for mediating blood pressure through vasoconstriction of blood vessels 
throughout the body (Yan et al., 2020). ACE2 is a functional dimer consisting of an N-
terminal peptidase domain and a c-terminal collectrin domain. The peptidase domain is a 
carboxypeptidase (cleaves one c-terminal peptide) and is responsible for cleavage of 
Angiotensin I into angiotensin-(1-9) and of octapeptide angiotensin-(1-8) into 
angiotensin-(1-7) (Huang, Yang, Xu, Xu, & Liu, 2020; Kowalczuk et al., 2008). The 
peptidase cleavage mechanism gives ACE2 an open and closed conformation. The 
collectrin domain is a transmembrane protein that anchors ACE2 to the plasma 
membrane (Zhang et al., 2007). It also contains the domains responsible for dimerization 
of ACE2 and is the chaperone for broad neutral amino acid transporter 1, known as 
B0AT1, which is responsible for neutral amino acid uptake in intestinal cells (Bader, 
Turner, & Alenina, 2020; Kowalczuk et al., 2008; Yan et al., 2020). Yan et al. 
determined that the structure of ACE2 is revealed in the presence of B0AT1, forming an 
ACE2-B0AT1 complex, which was determined by cryo-electron microscopy (cryo-EM) 
to be a dimer of heterodimers. They also revealed that the RBD of SARS-CoV-2 
recognizes and binds to the peptidase domain of ACE2. Using structural alignment of the 
RBD-ACE2-B0AT1 complex with the SARS-CoV-2 spike protein, they hypothesized 
that each ACE2-B0AT1 complex could bind two spike protein trimers simultaneously. 
Using cryo-EM, a 3D electron microscopy reconstruction of the RBD-ACE2-B0AT1 




complex was obtained, showing each peptidase domain bound to one RBD each, 
confirming their hypothesis was correct. Additionally, the closed state of ACE2 was 
observed in the RBD-ACE2-B0AT1 complex (Yan et al., 2020).  
Tai et al. conducted a study in which they reported that SARS-CoV-2 RBD binds 
strongly to human ACE2 receptors (Tai, He, et al., 2020). They identified the RBD 
containing portion of SARS-CoV-2 spike protein and using flow cytometry, found 
recombinant SARS-CoV-2 RBD protein bound to ACE2 receptors. Additionally, when 
the recombinant RBD is bound to ACE2, it prevented SARS-CoV-2 entry into ACE2 
expressing cells (Tai, He, et al., 2020). They conclude that RBD could serve as a viral 
attachment inhibitor against SARS-CoV-2 infection; however, this would not be an 
effective treatment as ACE2 is conformationally locked when in complex with RBD, and 
would not be able to function properly, causing pathophysiological effects (Bader et al., 
2020; Yan et al., 2020). Tai et al. also compared the binding affinity of SARS-CoV-2 
RBD to ACE2 with that of SARS-CoV RBD and MERS-CoV RBD. They found that 
SARS-CoV-2 RBD bound with much stronger affinity to ACE2 than SARS-CoV RBD, 
shown by EC50 values of 0.14±0.05µg/mL and 1.32±0.09µg/mL, respectively. MERS-
CoV RBD did not bind ACE2 since it uses the DPP4 receptor for cell entry (Tai, He, et 
al., 2020).  
Similarly, the binding motif of RBD to ACE2 was reported by Wang et al. (Wang 
et al., 2020). From previously published literature on SARS-CoV, the CTD of SARS-
CoV RBD was known to bind to ACE2, and that SARS-CoV-2 RBD behaved similarly. 
However, binding of SARS-CoV-2 RBD to ACE2 through the CTD had not been directly 




tested. They showed that SARS-CoV-2 RBD CTD had high affinity for ACE2 using flow 
cytometry.  Following this, to form the SARS-CoV-2 RBD CTD-ACE2 complex, an in 
vitro mixture of SARS-CoV-2 RBD CTD and ACE2 was prepared. The complex was 
isolated using Size Exclusion Chromatography (SEC). The crystal structure of the 
complex was then determined, enabling Wang et al. to confirm that the CTD of SARS-
CoV-2 RBD definitively binds to ACE2 (Wang et al., 2020).  
Huang et al. detail the structural and functional properties of the spike protein of 
SARS-CoV-2, revealing the behavior of RBD during attachment to ACE2. They note that 
the spike protein RBD domain has an “up” and “down” conformation, as previously 
determined through cryo-EM by Wrapp et al. and Walls et al.(Walls et al., 2020; Wrapp 
et al., 2020). RBD is in the “down” conformation when spike is not interacting with a 
host receptor and is referred to by Wrapp et al. as the prefusion conformation of the spike 
protein trimer. The prefusion trimer gets destabilized when the RBD (within S1) shifts to 
the “open” conformation to bind to ACE2.  
It is important to note that the Spike protein is highly immunogenic, and therefore 
would be the target for neutralizing antibodies (Walls et al., 2020). In a review by Yu, 
Xiang, et al., they report that after SARS-CoV-2 RBD was screened with neutralizing 
monoclonal antibodies, it was revealed that it consisted of a number of neutralizing 
epitopes (Yu et al., 2020). In a study conducted by Zost et al., they analyzed a panel 
(n=389) of human monoclonal antibodies to SARS-CoV-2 spike protein. They found a 
significant number of them that exhibited neutralizing activity and also block RBD 
interaction with ACE2 (Zost et al., 2020). Considering the immunogenicity of RBD and 




the RBD binding mechanism with ACE2, RBD of SARS-CoV-2 is a primary target for 
neutralizing antibodies and can elicit a strong host adaptive immune response. 
During an active infection, SARS-CoV-2 RNA and proteins are detectable in 
multiple bodily fluids, including saliva, tears, and feces (Kutti-Sridharan, Vegunta, 
Vegunta, Mohan, & Rokkam, 2020). Post-infection of SARS-CoV-2, seroconversion 
occurs, at which point the host adaptive immune system antibody production reaches 
peak levels. Long et al. conducted a study in which they observed antibody responses to 
SARS-CoV-2 in 285 COVID-19 patients (Long et al., 2020). Seroconversion of IgG or 
IgM occurred within 20 days after onset of symptoms before plateau. SARS-CoV-2 is 
detected using molecular assays, while the humoral response to SARS-CoV-2 is detected 
using serological assays. In a review by Younes et al., they discuss that the gold standard 
for detecting an active SARS-CoV-2 infection is using a molecular-based assay called 
quantitative real-time reverse transcriptase PCR, qRT-PCR (Toptan et al., 2020; Younes 
et al., 2020). qRT-PCR allows for the quantification of viral RNA by detecting the 
complementary DNA (cDNA). RNA gets reverse transcribed into cDNA, which is 
detected once enough replication cycles have been completed, achieving a detectable 
signal (Bustin & Mueller, 2005). The PCR quantitative output is fluorescence. 
Fluorescence occurs when a PCR product is amplified. A significant fluorescence 
increase is detected at a time inversely proportional to the copy number of the starting 
nucleic acid target (Bustin & Mueller, 2005). 
While qRT-PCR detects the genetic material of SARS-CoV-2 and is useful for 
diagnosing active SARS-CoV-2 infection, it cannot diagnose previous exposure to 




SARS-CoV-2. Determining if a given person has had a previous infection is important in 
tracing SARS-CoV-2 exposure throughout the population and assessing potential host 
immunity. Humoral response and previous SARS-CoV-2 exposure are determined using 
serological testing. Serological assays detect antibodies from patient plasma or serum that 
target SARS-CoV-2 immunogenic proteins(Lee, Lin, Renia, & Ng, 2020). There are three 
types of serological tests commercially used for SARS-CoV-2: Enzyme Immunoassays 
(Chemiluminescence Enzyme Immunoassays [CLIA] and Enzyme Linked Immuno-
Sorbent Assays [ELISA]) and Lateral Flow Immunoassays (LFIA) (Nicol et al., 2020; 
Younes et al., 2020). LFIA is similar to home pregnancy tests and personal blood glucose 
monitors for diabetes, in which a fluid analyte (i.e. blood, saliva, urine) flows across 
zones of polymeric strips. Antibodies that are specific for a target antigen within the 
analyte are bound to the polymeric strips. LFIA also is a rapid test that returns results 
within 5-30 minutes (Koczula & Gallotta, 2016). Enzyme immunoassays for SARS-CoV-
2 use a target antigen that binds to the well of a microplate (commonly 96-well plate), to 
which antibodies in human sera or plasma bind. The primary (1°) antibodies bound to the 
target immunogen are then bound by a secondary (2°) antibody that is not reactive to the 
target immunogen. The target immunogen-1° antibody-2° antibody complex is then 
detected. For CLIA, the 2° antibody is labeled with isoluminol, which is activated to 
luminesce with an oxidant (i.e. hydrogen peroxide), allowing the amount of 1° antibody 
bound to be measured with reference to the luminescence emitted (Cinquanta, Fontana, & 
Bizzaro, 2017). For ELISA, the 2° antibody is conjugated to horseradish peroxidase 
(HRP) or alkaline phosphatase (ALP), which is then detected with substrate solution, 




allowing for the amount of 1° antibody bound to be measured with reference to the 
Optical Density (OD) of the well. As earlier mentioned, in addition to Spike protein, 
SARS-CoV-2 also consists of three other main structural proteins: Envelope protein, 
Membrane Protein, and Nucleocapsid Protein. Of these structural proteins, Nucleocapsid 
and Spike protein (including RBD) are used in SARS-CoV-2 serological assays, as 
Nucleocapsid protein is amply expressed during infection and Spike protein is highly 
exposed. 
In a study published in 2004, by Sun et al., they examined antigenic cross-
reactivity between the Nucleocapsid protein of SARS-CoV and other known 
coronaviruses, and they concluded that the SARS-CoV nucleocapsid protein was 
responsible for antigenic cross-reactivity with sera positive for other coronaviruses, 
noting that nucleocapsid protein is the most conserved protein between coronaviruses 
(Sun & Meng, 2004). In a similar study published in 2021 by Tso et al., it was shown that 
SARS-CoV-2 nucleocapsid protein was cross-reactive with known endemic 
coronaviruses (Tso et al., 2021). As nucleocapsid protein is the most conserved protein 
among coronaviruses, humoral responses to nucleocapsid protein are not highly specific 
to SARS-CoV-2 as antibodies are cross-reactive with nucleocapsid from various other 
endemic viruses (i.e. HCoV-229E, -NL63, -OC43, -HKU1), resulting in false positive 
results and decreased assay specificity (Younes et al., 2020).  
As previously mentioned, in serological assays for SARS-CoV-2, recombinant 
nucleocapsid, spike protein, and receptor binding domain have been used. Since it is not a 
trimer in native form, to allow for trimerization of recombinant receptor binding domains, 




a trimerization domain would need to be used. Foldon is the C-terminal domain of the 
bacteriophage T4 head, Fibritin. Fibritin is a trimeric protein that has a 486 amino acid 
sequence and has chaperone, sensory, and structural properties (Meier, Guthe, Kiefhaber, 
& Grzesiek, 2004). Foldon is critical for the trimerization of fibritin (Letarov, Londer, 
Boudko, & Mesyanzhinov, 1999; Meier et al., 2004). Several studies investigating the 
production of trimeric recombinant proteins have been conducted that demonstrate that 
foldon can be used as a stable trimerization domain (i.e., fusion with influenza 
hemagglutinin or rabies virus glycoprotein) (Chen et al., 2010; Frank et al., 2001; 
Papanikolopoulou, Forge, Goeltz, & Mitraki, 2004; Sissoeff, Mousli, England, & 
Tuffereau, 2005; Welsh, Lu, He, Greenberg, & Swartz, 2012). Specifically, for 
coronaviruses, this was demonstrated in a study conducted by Tai et al., in which they 
fused foldon to the RBD of MERS-CoV (Tai et al., 2016). In the study, they fused foldon 
to the c-terminus of MERS-CoV RBD, along with a 6X-histidine tag to allow for affinity 
purification of the trimeric RBD. They then characterized the protein, determining its 
antigenicity, receptor binding affinity, immunogenicity, neutralization potential, and 
efficacy in protecting human DPP4-transgenic mice in a MERS-CoV challenge. They ran 
neutralization assays on immunized mice sera to assess antigenicity and neutralization 
potential. They found that the MERS-CoV RBD foldon fusion successfully protected 
mice from infection and elicited strong MERS-CoV RBD specific neutralizing antibody 
responses. Li et al. conducted a similar study, in which they fused foldon to the c-
terminus of SARS-CoV S1 subunit and S protein along with a 9X histidine tag for 
affinity purification, assessing their immunogenicity and efficacy in protecting mice from 




a SARS-CoV challenge(J. Li, Ulitzky, Silberstein, Taylor, & Viscidi, 2013). They 
compared foldon fused SARS-CoV S1 and Spike protein to monomeric SARS-CoV S1 
and Spike protein. They found that each protein (monomeric Spike and S1, trimeric 
foldon fused Spike and S1) successfully protected mice from infection and that the 
SARS-CoV spike foldon fusion elicited the highest level of neutralizing antibodies 
compared to the other constructs they tested.  
Due to Spike protein’s structural and functional similarity between coronaviruses, 
these studies provide insight that suggests the potential efficacy of a SARS-CoV-2 RBD-
foldon fusion as an antigen in a diagnostic assay (Lu et al., 2020; Sivaraman, Er, Choong, 

















II. INSTRUMENTATION AND EQUIPMENT 
For the assays and experiments detailed in section III, the following materials were used: 
Bio-rad CriterionTM Electrophoresis Cell 
CriterionTM XT 12% Bis-Tris pre-cast gels 
Bio-rad 1X XT-MES running buffer 
GE AmershamTM Imager 600 
Bio-rad Trans-Blot® TurboTM Transfer System 
Thermo ScientificTM MaxQTM 2000 Orbital Shaker 
GE AmershamTM ECLTM Prime Western Blotting Detection Reagent 
New England Biotech Stable Competent E. Coli cells 
OMEGA Bio-tek E.Z.N.A Plasmid DNA Midi Prep Kit 
Invitrogen mMESSAGE mMACHINETM T7 Kit 
Precellys® 24 Tissue Homogenizer 
Thermo ScientificTM Sorvall Legend XTR Centrifuge 
Sartorius Stedim Biotech SartoScale 0.65 µm Disposable Filters 
Thermo ScientificTM NalgeneTM Rapid-FlowTM Sterile Single Use 0.2 µm Filter 
GE ÄKTA Pure Chromatography System 
GE TALON® SuperflowTM Resin 
Intermountain Life Sciences 1x Phosphate-Buffered Saline without Calcium and 
Magnesium  
Millipore Amicon® Ultra-15 Ultracel® Regenerated Cellulose 10000 Molecular Weight 
Cut-Off/Nominal Molecular Weight Limit (MWCO/NMWL) Centrifugal Filters 




Thermo ScientificTM Heraeus Multifuge X3R Centrifuge 
PALL Life Sciences Nanosep with 0.2 µm wwPTFE 
Thermo Fisher NanodropTM 1000 
Thermo Scientific 96-well microplates  
Eppendorf Xplorer 50-1200 µL Multichannel Repeater Pipette 
BioTek® EL406 Plate Washer 
Thermo Scientific PierceTM Protein-Free PBS Blocking Buffer 
Thermo Scientific 1-StepTM Ultra TMB-ELISA 



















A. Plasmid Design 
To construct RBD-foldon, the Foldon DNA sequence was added to the 3’ end of 
the RBD DNA sequence using a Glycine-Serine (GGGGS) linker, along with the DNA 
sequence encoding a C-terminal 6x histidine tag. A signal peptide (BPT1_BOVIN 
Pancreatic Trypsin Inhibitor) was also added to the 5’ end of the RBD DNA sequence. 






VLLSTFLG)(HHHHHH). This fused sequence was inserted in a Geneware® plasmid 
expression vector. The Geneware® vector includes DNA encoding tobacco mosaic virus, 
enabling protein expression in Nicotiana benthamiana plants. The plasmid was 
assembled for bacterial expression by ATUM (Newark, CA). 
B. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 SDS-PAGE samples were prepared using three volumes of protein sample and 
one volume 4X SDS loading dye. SDS loading dye (4X) was made with 6.25 mL of 1M 
Tris pH 7 buffer, 5 mL 100% glycerol, 4 mL 10% sodium dodecyl sulfate (SDS), 2 mL 
β-mercaptoethanol (BME), 7.75 mL de-ionized water, and 10 mg bromophenol blue. Bio-




rad CriterionTM Electrophoresis Cells and CriterionTM XT 12% Bis-Tris pre-cast gels 
were used. Gels were ran using 1X XT-MES running buffer (Bio-rad) at 200V for 45 
minutes. Stain solution was made using 2 g of Coomassie Blue R-250, 200 mL acetic 
acid, 800 mL 100% ethanol, and 1 L de-ionized water. De-stain solution was made using 
1.65 L de-ionized water, 150 mL acetic acid, and 200 mL 100% ethanol. Following 
staining and de-staining, images were taken using colorimetric transillumination (GE 
AmershamTM Imager 600). 
C. Western Blotting 
 First, SDS-PAGE was run. The gel was not stained, and the gel contents were 
transferred to a PVDF membrane using a Western Blot transfer kit (Bio-rad Trans-Blot® 
TurboTM Transfer System). Powdered milk was resolubilized in 50 mL of 1x phosphate-
buffered saline tween-20 (PBST) solution to make a 3% w/v solution. 20 mL of 3% 
PBST-milk was then used to make 60 mL of 1% PBST-milk. Mouse anti Histidine 
Primary antibody (GenScript Catalog No. A00186-100) was diluted 1:3,000. Goat anti 
Mouse Secondary antibody (Southern Biotech Catalog No. 1030-05) was diluted 1:6,000. 
Primary and secondary antibody dilutions were each made in 30 mL of 1% PBST-milk. 
All wash steps were done three times with 1x PBST solution. The membrane was 
manually washed, then placed in 30 mL of 3% PBST-milk and incubated on an orbital 
shaker at 100 RPM for 12-16 hours at 4°C. The membrane was then washed, placed in 30 
mL primary antibody solution, and placed on an orbital shaker at 100 RPM for 1 hours at 
room temperature. Following this, the membrane was washed, placed in 30 mL 
secondary antibody solution, and placed on an orbital shaker at 100 RPM for 1 hours at 




room temperature. The membrane was washed a final time, then 1 mL of development 
solution was washed over the membrane. Development solution was made with 0.5 mL 
hydrogen peroxide and 0.5 mL luminol (GE AmershamTM ECLTM Prime Western 
Blotting Detection Reagent). Images were taken using epifluorescence (GE AmershamTM 
Imager 600). 
D. Plasmid Amplification and Virion Extraction 
The plasmid was transformed in E. coli bacteria (New England Biotech Stable 
Competent E. coli cells). The bacteria were lysed, and the recombinant DNA was isolated 
(OMEGA Bio-tek E.Z.N.A Plasmid DNA Midi Prep Kit). Prepped DNA was then 
transcribed to RNA (Invitrogen mMESSAGE mMACHINETM T7 Kit). The transcription 
reaction was verified through DNA gel electrophoresis with Ethidium Bromide (Bio-Rad) 
used as an intercalating agent. For Nicotiana benthamiana inoculation, transcribed RNA 
was mixed with plant inoculation buffer (60mM Glycine, 36mM Potassium Phosphate 
Dibasic Trihydrate, 13mM Sodium Pyrophosphate Decahydrate, 55mM Bentonite, and 
94mM Celite) to a concentration of 0.5 ng/µL. This mixture was used to inoculate leaves 
4 and 5 of 28-35 days post sow Nicotiana benthamiana plants. Plants were harvested 5 
days post inoculation and virion was extracted to verify TMV expression. Virion was 
extracted by PEG Precipitation (Corman et al., 2020). Virion PEG precipitation samples 
were run on SDS PAGE to verify virion had been isolated. The concentration of virion 
was determined from the absorbance at a wavelength of 260 nm (Thermo Fisher 
NanodropTM 1000). Virion was aliquoted and stored at -20°C to be used to inoculate 
additional plants to produce RBD-foldon protein. 




E. RBD-foldon Nicotiana benthamiana Infiltration 
Nicotiana benthamiana plants were grown to 28-35 days post sow, then infiltrated 
with 100 µL of 0.5 ng/µL virion, using plant inoculation buffer to allow virion entrance 
into plants. Whole plants were harvested at 14 Days Post-Infiltration and harvested tissue 
was stored at -20°C. 
F. RBD-foldon Extraction Buffer Panel 
 A panel of buffers was used to determine ideal buffer conditions for extraction of 
RBD-foldon. Twelve buffers were tested: Sodium Acetate pH 4 and 5, Sodium Phosphate 
pH 6 and 7.5, Tris pH 9 and 10, each with and without 200 mM Sodium Chloride. All 
buffers were made at 50 mM concentration with 10 mM Sodium Metabisulfite and 20 
mM Ascorbic Acid. For each buffer, 0.5 grams of RBD-foldon infected plant tissue was 
homogenized at a 1:1 w/v ratio. A Precellys 24 Tissue Homogenizer was used at 
6500RPM. Samples were taken at each step and analyzed with SDS-PAGE. 
G. RBD-foldon Extraction 
RBD-foldon protein was extracted from frozen inoculated plant tissue. Extraction 
buffer (50 mM Sodium Phosphate/200 mM NaCl buffer at pH 7.5) was made with 20 
mM Ascorbic Acid and 10 mM Sodium Metabisulfite used as antioxidants. Tissue was 
homogenized at a 1:1 w/v ratio with extraction buffer. After blending, the homogenate 
was first filtered through two layers of Cheesecloth and one layer of Miracloth, then 
centrifuged (Thermo ScientificTM Sorvall Legend XTR Centrifuge) at 15,000 x g for 15 
minutes. This cloth filtering and centrifugation step was repeated, then the homogenate 




was filtered through 2 layers of Cheesecloth and 1 layer of Miracloth and stored at 4°C to 
incubate 12-16 hours. Following incubation, the homogenate was centrifuged at 15,000 x 
g for 15 minutes, then flowed through a 0.65µm glass fiber filter (Sartorius Stedim 
Biotech SartoScale Disposable) using a peristaltic pump. This homogenate was then 0.2 
µm vacuum filtered (Thermo ScientificTM NalgeneTM Rapid-FlowTM Sterile Single Use). 
Samples were taken at each step and analyzed with SDS-PAGE. 
H. RBD-foldon Purification 
1. FPLC 
The 0.2 µm filtered homogenate was immediately loaded for FPLC (GE ÄKTA 
Pure Chromatography System). RBD-foldon was isolated from the homogenate using 
Cobalt IMAC Column (GE TALON® SuperflowTM Resin), measured to a column 
volume of 10 mL, isolating RBD-foldon using the 6x histidine tag. The wash buffer 
(Buffer A) used was 50 mM Sodium Phosphate with 200 mM NaCl at pH 7.5. Elution 
buffer (Buffer B) used was 50 mM Sodium Phosphate, 200 mM NaCl, and 500 mM 
Imidazole at pH 7.5. A buffer gradient from 100% buffer A/0% buffer B to 0% buffer 
A/100% buffer B over 20 column volumes was used to separate and elute product. 
Samples were taken of chromatography wash, flow-through, and elution fractions and 
analyzed with SDS-PAGE. 
2. UF/DF 
Following chromatography, RBD-foldon elution fractions were combined into 
one volume. Utilizing UF/DF, volume was buffer exchanged from imidazole-containing 




buffer to 1x phosphate-buffered saline (Intermountain Life Sciences), and concentrated. 
For UF/DF of RBD-foldon containing volume, 10,000 molecular weight cut-off/nominal 
molecular weight limit (MWCO/NMWL) centrifugal filters (Millipore Amicon® Ultra-
15 Ultracel® Regenerated Cellulose) were used with a centrifuge setting of 4,000 x g 
(Thermo ScientificTM Heraeus Multifuge X3R Centrifuge). Following UF/DF, the RBD-
foldon containing retentate was 0.2 µm centrifugal filtered (PALL Life Sciences Nanosep 
with 0.2 µm wwPTFE). The concentration of 0.2 µm filtered RBD-foldon containing 
retentate was determined using a spectrophotometer (Thermo Fisher NanodropTM 1000) 
to obtain the absorbance at a wavelength of 280 nm. Samples were taken of the load, 
permeate, and retentate and analyzed with SDS-PAGE. Additionally, the same samples 
run on SDS-PAGE were ran on Western Blots. For SDS-PAGE and Western Blotting, 10 
µg and 1 µg of RBD-foldon was loaded, respectively. 
I. Sample Collection 
A total of 128 human sera samples were collected. There were 82 total COVID 
positive samples. Of the positives, there were 46 hospitalized patient samples and 36 non-
hospitalized patient samples. All positive samples were RT-PCR-positive and RBD IgG 
Seropositive, or either Spike IgG or IgM Seropositive. There were 46 total negative 
samples. Of the negatives, there were 33 pre-COVID negative samples, 11 pre-COVID 
negative HIV-positive samples, and 2 hospitalized patient samples (patients that were 
hospitalized during the pandemic for reasons not related to COVID-19). Hospitalized 
samples were obtained from Norton Hospital patients. Non-hospitalized samples were 




obtained from healthcare workers and Co-Immunity (University of Louisville IRB# 
20.0312). Negative samples were obtained from two biorepositories. 
J. RBD-foldon Serological ELISA 
All ELISAs were ran on 96-well microplates (Thermo Scientific) using RBD-
foldon as the coating immunogen (Figure 2).  
1. Antigen Coating Optimization 
Initially, four coating concentrations were used to determine the optimal 
concentration of RBD-foldon. Microplates were coated with 100 µL of each RBD-foldon 
concentration diluted in PBS with a multichannel repeater pipette (Eppendorf Xplorer 50-
1200 µL). Plates were then placed in 4°C for 12-16 hours, then washed three times with 
300 µL per well of PBS-T. This washing scheme was repeated after each step and done 
either manually using a multichannel repeater pipette or using a plate washer (BioTek® 
EL406). Next, all plates were blocked at room temperature for 1-2 hours with 300 µL 
protein-free buffer (Thermo Scientific PierceTM Protein-Free PBS Blocking Buffer) per 
well. During blocking, within a biosafety cabinet, 46 samples (23 hospitalized positive 
and 23 negatives) were diluted to 1:50 in protein free buffer. Plates were washed, then 50 
µL of protein free buffer was added to each well of each plate. Samples were added in 
duplicate, leaving four blanks per plate to allow for the average background optical 
density (OD) to be obtained. 50 µL of each 1:50 sera sample dilution was added to 92 
wells total, resulting in a final dilution of 1:100. 50 µL of protein free buffer was added to 
the remaining four wells. The plates were then incubated at 37°C for 30 minutes. During 




incubation, secondary antibody dilution was prepared. Rabbit anti Human IgG-HRP was 
diluted to 1:10000 in protein free buffer. Following incubation, plates were then washed 
in the biosafety cabinet, and 100 µL of secondary antibody dilution was added to every 
well. The plates were then incubated at room temperature for 1 hour. Following 
incubation, plates were washed, and 100 µL of room temperature TMB substrate 
(Thermo Scientific 1-StepTM Ultra TMB-ELISA) was added to every well. After 15 
minutes, 100 µL of stop solution (1N HCl) was added to the TMB in each well. Optical 
density (OD) of each well was read at a wavelength of 450 nm using a plate reader 
(BioTek® SynergyTM HT). Data was exported to excel for analysis.  
2. Antibody Class Specificity  
 The 5 µg/mL RBD-foldon coating was used on all subsequent plates and the 
previous 23 hospitalized positive and 23 negative samples were replicated with IgG-HRP 
secondary antibody. An additional 23 hospitalized positive, 36 non-hospitalized positive, 
and 23 negative samples, along with a positive and negative control (positive control was 
10-fold higher OD than the negative control) and blank, were assessed for IgG response, 
for a total of 82 positive and 46 negative samples. All samples were added to the plate in 
duplicate and each assay was replicated three times. The same 82 positive and 46 
negative samples were evaluated for IgA and IgM responses by altering the secondary 
antibody. The rabbit anti Human IgA-HRP secondary antibody at 1:10,000 dilution in 
protein free buffer was used to assess IgA response and Rabbit anti Human IgM-HRP 
secondary antibody at 1:10,000 dilution in protein free buffer was used to assess IgM 
response. All plates were incubated with secondary antibody at room temperature for 1 




hour. Following incubation, plates were washed, and 100 µL of room temperature TMB 
substrate was added to every well. After 15 minutes, 100 µL of stop solution (1N HCl) 
was added to the TMB in each well. Optical density (OD) of each well was read at a 
wavelength of 450 nm using a plate reader. Data was exported to excel for analysis.  
3. Lot Variability  
 ELISAs assessing the IgG response were performed as previously described using 
the IgG-HRP secondary antibody but with four freshly purified RBD-foldon lots. Each 
single lot was coated at 5 µg/mL on one half of a plate (i.e., Lot 1 coated on Plate 1: 
columns 1-6, Lot 2 coated on Plate 1: columns 7-12, Lot 3 coated on Plate 2: columns 1-
6, Lot 4 coated on Plate 2: columns 7-12). All samples were tested in triplicate with; six 
positive samples, six negative samples, positive control, negative control, and blank per 
lot. Following analysis in Excel, analyzed data was input to Graphpad PRISM for further 
analysis. 
4. Antibody Titration 
 IgG antibody titers to RBD-foldon were determined for all 82 positive samples. 
RBD-foldon was coated at 5 µg/mL on each plate. Six samples, positive/negative control, 
and blank were run per plate. Samples were analyzed in duplicate with three-fold serial 
dilutions, from 1:100 to 1:72,900. IgG-HRP was used as secondary antibody. Blocking, 
washing, incubation, and color development were the same as previously described. Data 
was exported to excel for analysis.  
 





FIGURE 2 – RBD-foldon ELISA Layout (1°Antibody: Human Sera anti-RBD, 2°Antibody: Rabbit anti-Human HRP 
Conjugate, TMB: Reporter Enzyme) 
 
K. Data Analysis 
ELISA data was analyzed using Microsoft Excel or Graphpad PRISM. For 
ELISAs of each differing RBD-foldon coating (concentration or lot) or secondary 
antibody (IgG/IgA/IgM), the OD of blank wells were averaged, and subtracted from the 
OD of all sample containing wells. Then, the OD of sample duplicates/triplicates were 
averaged and used to generate Receiver Operator Characteristic (ROC) Curves to assess 
sensitivity and specificity of RBD-foldon ELISAs. For lot variability ELISAs only, 
analyzed data from excel was input to Graphpad PRISM, and assessed using a one-way 
ANOVA and Tukey test. For antibody titration, the OD of duplicate blanks were 
averaged and subtracted from all sample containing wells on each plate. Next, the OD of 
duplicate samples were averaged. The cutoff OD for antibody titer determination was set 




at 0.3 OD absorbance units (AU) above that of the mean negative control OD. RBD-
foldon antibody titers were plotted against PRNT50 titers and Pearson’s r values were 
























IV. RESULTS AND DISCUSSION 
A. Aim 1: Establish a reproducible purification method for plant expressed RBD-foldon. 
In order to develop an RBD-foldon serological assay, a consistent expression 
platform needed to be established. The tobacco mosaic virus (TMV) viral vector 
expression system was chosen due to its speed and consistency. TMV virion expressing 
RBD-foldon was extracted from Nicotiana benthamiana plants. TMV coat protein is 17.5 
kilodaltons (kD) in size and can be seen in Figure 3. Coat protein presence is associated 
with viral RNA translation (Liu & Nelson, 2013), and therefore the presence of coat 
protein on the gel indicates that the viral vector had infected and was replicating 
throughout plants, and should be expressing RBD-foldon. 
Following the establishment of a plant expression system for RBD-foldon, 
multiple extraction buffers were evaluated for protein extraction. The results of the 
extraction buffer panel indicated that buffer containing 50 mM Sodium Phosphate, 200 
mM Sodium Chloride, at pH 7.5 was sufficient to extract RBD-foldon from Nicotiana 
benthamiana tissue (Figure 4).  RBDFoldon extraction and purification samples were ran 
on SDS-PAGE (Figures 5 and 6). In figure 5, the large subunit of Rubisco is present at 
50kD. Rubisco is the main carboxylase of the Calvin cycle and the most prevalent 
enzymes in the biosphere (Flamholz et al., 2019). It contains a large subunit of ~50 kD 
and a small subunit of 10-15 kD in size, either of which can be seen on SDS-PAGE when 
extracted in large enough quantities. In wells 2-9, TMV coat protein is present at 17.5 
kD, showing that the expression vector was translated in plant tissue. RBD-foldon is 
31.485 kD in size and can be seen as the dominant band in wells 10-13, confirming RBD-




foldon was isolated from the homogenate. In figure 6, a band at 31.485 kD was visible in 
the combined elution fraction sample (ultrafiltration/diafiltration load) and is the most 
prominent band in the ultrafiltration/diafiltration (UF/DF) retentate sample. Western 
Blotting confirmed that RBD-foldon was isolated, as a significant band reactive to 6x His 
antibody at 31.485 kD was detected (Figure 7).  
Four additional lots (5-8) of RBD-foldon were expressed and purified to examine 
lot-to-lot variability. The volume of plant tissue used to produce previous lots required 
the use of an automated chromatography system. Since the volume of plant tissue was 
significantly less than previously used, batch purification was performed (Figure 8). 
RBD-foldon lots 5, 6, 7, and 8 were concentrated to 2.13 mg/mL, 2.73 mg/mL, 1.92 
mg/mL, and 3.22 mg/mL, respectively. The UF/DF of each lot can be seen in Figure 9, 
with 5 µg of each lot ran in the “Retentate” lanes. To test the quality of each lot, the 
serological assay was run with each lot, using six positive samples, six negative samples, 
positive and negative control, and blank. Lot 5 was then used as a reference for lots 6, 7, 
and 8. The percent difference in absorbance between samples tested on each lot relative 
to lot 5 was determined.  
A one-way ANOVA and Tukey’s post-hoc tests were run to compare the variance 
of negative sample absorbance between lots 6, 7, and 8 and Positive Sample optical 
densities between lots 6, 7, and 8 (Figure 10). No statistical differences were observed in 
response to any of the three lots (α=0.05). Therefore, it was concluded that RBD-foldon 
can be reproduced using the methods previously described with no statistical difference 
in sera response between lots. 





FIGURE 3 – Virion Extraction SDS-PAGE [Order from left to right: (1) protein ladder (2) homogenate supernatant 
post centrifugation (3) miracloth and cheesecloth filtered supernatant (4) post addition of PEG (5) post 2-hour 




FIGURE 4 – RBD-foldon Extraction Buffer Panel SDS-PAGE [Order from left to right: (1) protein ladder (2&3) 
50mM Sodium Acetate pH 4 w/o and w/200mM NaCl (4&5) 50mM Sodium Acetate pH 5 w/o and w/200mM NaCl 
(6&7) 50mM Sodium Phosphate pH 6 w/o and w/200mM NaCl (8&9) 50mM Sodium Phosphate pH 7.5 w/o and 
w/200mM NaCl (10&11) 50mM Tris pH 9 w/o and w/200mM NaCl (12&13) 50mM Tris pH 10 w/o and w/200mM 
NaCl (14) 1x XTMES (15) protein ladder] 






FIGURE 5 – RBD-foldon Extraction and Cobalt Affinity Chromatography SDS-PAGE [Order from left to right: (1) 
protein ladder (2) Miracloth and cheesecloth filtered homogenate (3) Post 1st Centrifugation (4) Post 2nd 
Centrifugation (5) Post 16 hour 4°C incubation (6) Post 3rd Centrifugation (7) Post 0.65µm Glass Fiber filtration (8) 
Post 0.2µm bottle-top vacuum filtration (9) IMAC flow through (10) IMAC Wash (11-17) Elution fractions 1A1-1A5, 
1B1-1B3 (18) protein ladder] 
 
 
FIGURE 6 – RBD-foldon Ultrafiltration/Diafiltration SDS-PAGE [Order from left to right: (1) protein ladder (2) Load 
– combined IMAC elution fractions 1A1-1A4 (3) Permeate (4) Retentate (5) protein ladder] 










FIGURE 8 – Lot Variability Batch Purification SDS-PAGE [Order from left to right: (1) protein ladder (2,6,10,14) Lot 
5-8 0.2µm filtered homogenate (3,7,11,15) Lot 5-8 Flow through (4,8,12,16) Lot 5-8 Wash (5,9,13,17) Lot 5-8 Eluate 
(18) protein ladder] 
 





FIGURE 9 – Lot Variability UF/DF SDS-PAGE [Order from left to right: (1) protein ladder (2-5) Lot 5-8 Eluate (6-9) 
Lot 5-8 Permeate (10-13) Lot 5-8 Retentate (14-17) Lot 5-8 0.2µm filtered Retentate (18) protein ladder] 
 
 
FIGURE 10 – Mean Percent Difference of Lots 6-8 from Reference (Positive Samples n=6, Negative Samples n=6) 
 




B. Aim 2: Establish a serological assay using RBD-foldon as the target antigen. 
Running SDS-PAGE and western blotting of RBD-foldon allowed for verification 
of the expression and isolation of RBD-foldon, and RBD-foldon -targeting serological 
ELISA development could begin. The first step in assay development was determining 
coating concentration of RBD-foldon. In developing serological assays for detecting viral 
responses, high sensitivity and specificity are imperative. Sensitivity relates to the 
probability of correctly identifying a positive sample, or True Positive Rate (TPR). For 
example, the highest possible sensitivity of 1 means that 100% of positive samples will 
be correctly identified by the assay. Conversely, specificity relates to the probability of 
correctly identifying a negative sample, or True Negative Rate (TNR). So, the highest 
possible specificity of 1 means that 100% of negative samples will be correctly identified 
by the assay. As the sensitivity decreases, the probability of incorrectly identifying a 
positive sample as negative, or the False Negative Rate (FNR), increases. Similarly, as 
the specificity decreases, the probability of incorrectly identifying a negative sample as 
positive, or the False Positive Rate (FPR), increases. ROC Curves were generated to 
examine the relationship between true positive rate and false positive rate and determine 
an acceptable cutoff optical density value for identifying positive and negative samples. 
For the RBD-foldon serological assay, the optimal cutoff optical density value is 
characterized by both a high true positive rate (≥90%) and low false positive rate (≤10%).  
ELISAs were ran with four coating concentrations—from low to high: 0.5 µg/mL, 
1 µg/mL, 2.5 µg/mL, and 5 µg/mL. At 100% sensitivity (TPR=100%), for RBD-foldon 
coating concentrations of 0.5, 1, 2.5, and 5 µg/mL, the optimal OD cutoffs are 0.09175, 




0.1905, 0.278, and 0.47925, respectively (indicated by yellow points in Figure 11A-D). 
These OD cutoffs would yield specificities of 34.78%, 95.65%, 82.60%, and 95.65%, 
respectively.  Conversely, at 100% specificity (TNR=100%), for RBD-foldon coating 
concentrations of 0.5, 1, 2.5, and 5 µg/mL, the optimal OD cutoffs are 0.17975, 0.256, 
0.4535, and 0.71125, respectively (indicated by red points in Figure 11A-D). These OD 
cutoffs would yield sensitivities of 65.22%, 86.95%, 95.65%, and 95.65%, respectively 
(Figure 11A-D).  
At 100% sensitivity or 100% specificity, 0.5 µg/mL yielded both the lowest 
specificity and sensitivity of the four concentrations. This produced largely inaccurate 
identification of positive and negative samples and suggests that 0.5 µg/mL coating was 
not able to elicit sufficient binding of SARS-CoV-2 induced IgG antibodies. Therefore 
0.5 µg/mL was not an optimal coating concentration. At 100% sensitivity, 1 µg/mL 
coating had the lowest specificity, while 2.5 and 5 µg/mL had the same specificity. 
Conversely, at 100% specificity, 2.5 µg/mL coating had the lowest sensitivity, while 1 
and 5 µg/mL had the same sensitivity. When sensitivity or specificity is at 100%, while 1 
µg/mL and 2.5 µg/mL coatings do yield high specificity/sensitivity, 5 µg/mL coating 
concentration yields a sensitivity or specificity that is equal to or higher than both 1 
µg/mL and 2.5 µg/mL. Additionally, comparing the deviation between optical densities 
of 1 µg/mL, 2.5 µg/mL, and 5 µg/mL (Table I), 5 µg/mL has the greatest deviation in OD 
between positive and negative samples, further supporting the selection of 5 µg/mL as the 
concentration to proceed with the following studies.  
 





RBD-foldon Coating Concentration Optical Densities (Row 1) Highest Negative OD (Row 2) Lowest-Positive/Cut-off 




FIGURE 11 – ROC Curves for Varying RBD-foldon Coating IgG Responses (positive sample n=23, negative sample 
n=23) (A) 0.5µg/mL (B) 1µg/mL (C) 2.5µg/mL (D) 5µg/mL 
 
A key relationship is that, for serological assays, as specificity of the assay 
increases, sensitivity decreases, and as sensitivity of the assay increases, specificity 




decreases. The magnitude of this inverse relationship differs between assays. In choosing 
a cutoff OD for SARS-CoV-2 serological assays, two scenarios must be considered: 1) a 
specificity of 100% will correctly classify all individuals with antibodies but increase the 
probability of telling an individual they do not have antibodies when they do (a false 
negative diagnosis) and 2) a sensitivity of 100% will correctly classify all individuals 
without antibodies but increase the probability of telling an individual they have 
antibodies when they do not (a false positive diagnosis). The former maximizes 
specificity, sacrificing a percentage of assay sensitivity. The latter maximizes sensitivity, 
sacrificing a percentage of assay specificity. Assuming all antibodies are protective, 
individuals that are given a false positive result will be at risk for infection, potentially 
resulting in a decrease in adherence to practices that reduce viral spread and an increase 
in cases. Individuals that are given a false negative result will not be at the risk of 
infection and would not pose a negative societal impact on reducing viral spread. 
Considering each scenario, a cutoff OD should be chosen that yields both high sensitivity 
and specificity, but with emphasis placed on maximizing specificity.  
Hospitalized samples yielded a specificity of 95.65% and sensitivity of 93.4% 
(Figure 12A), while Non-Hospitalized samples yielded a specificity of 95.65% and 
sensitivity of 86.11% (Figure 12B). Plotting both hospitalized and non-hospitalized 
positives sera samples together, they yielded a specificity of 95.65% and sensitivity of 
90.24% (Figure 12C). When comparing the separate ROC curves for hospitalized 
positives and non-hospitalized positives, they yielded the same specificity and similar 
sensitivity, at similar cutoff optical densities. For the non-hospitalized positives, a cutoff 




of 0.787 was determined, while for the hospitalized positives, the cutoff determined was 
0.831. Plotting all positives together, a cutoff of 0.787 was determined. Cutoff OD were 
determined by selecting an OD that yielded the highest possible sensitivity with a 
specificity of at least 95%.  
After determining sensitivity and specificity, positive and negative predictive 
value (PPV and NPV) can be calculated. Assay PPV and NPV are determined based on 
sensitivity, specificity, and disease prevalence. Prevalence is a measure of the percentage 
of a population affected by a disease at a given timepoint and varies depending on what 
geographic area and timepoint it is measured across and within. Prevalence is calculated 
by taking the sum of the number of true positives and negatives and dividing that by the 
number of true positives, true negatives, false positives, and false negatives. PPV is 
defined as the probability that those who test positive are true positives, while the NPV is 
defined as the probability that those who test negative are true negatives. For example, 
with a specificity of 95% and sensitivity of 90%, for a high prevalence i.e., 50%, the PPV 
and NPV will both be above 90%, with PPV higher than NPV. For a lower prevalence 
i.e., 10%, the PPV will drop to ~70%, while the NPV will increase to ~99%. This means 
that for a geographical region with a lower prevalence, the probability that those who test 
negative are true negatives is very high. For the present assay, the negative predictive 
value is very important as a high value would show that the assay can identify the 
majority of individuals in the region that have not been exposed and/or do not have 
protection from SARS-CoV-2, aiding individuals in adhering to guidelines that would 
protect them from contracting SARS-CoV-2. 






FIGURE 12 – ROC Curves for Patient IgG Response (A) Hospitalized Positive sera n=46, Negative sera n=46 (B) 
Non-Hospitalized Positive sera n=36, Negative sera n=46 (C) All (Hospitalized and Non-Hospitalized) Positive sera 
n=82, Negative sera n=46 
 
To examine antibody class specificity to RBD-foldon, ROC curves were 
constructed and examined for patient IgA and IgM responses. A method for determining 
optimal cutoff OD is choosing the point closest to the (0,1) corner of the ROC curve. The 
closer the curve to the 45° diagonal, the less accurate the test. Using this method for the 
IgA ROC curve in Figure 13A, the optimal OD was 0.253, with sensitivity and specificity 
of 60.98% and 80.43%, respectively. Using the same method that was used to determine 
IgA sensitivity and specificity, from the IgM ROC curve in Figure 13B, the optimal OD 
was 0.5453, with sensitivity and specificity of 70.73% and 82.61%, respectively.  




The sensitivity and specificity for IgA was very low. Sensitivity and specificity of 
IgM was higher than that of IgA, but not as high as IgG. During infection, IgM is 
produced before IgG but declines in concentration, comparatively, as the number of IgG 
antibodies increase (Younes et al., 2020). IgA antibodies are typically protective 
however, they may be specific for other epitopes of the Spike protein besides RBD, 
explaining the low response to an RBD antigen (Sterlin et al., 2021). Additionally, IgM 
and IgA antibodies have varying seroconversion times and are less prevalent in sera than 
IgG antibodies (Long et al., 2020; Sterlin et al., 2021; Younes et al., 2020). Considering 
this, and due to the varying timepoints of infection for each collected sera sample used, 
IgM and IgA could be used qualitatively to determine general exposure to SARS-CoV-2 




FIGURE 13 – ROC Curves for Patient IgA and IgM Response (A) IgA Response of all Positive sera n=82, Negative 
sera n=46 (B) IgM Response of all Positive sera n=82, Negative sera n=46  
 




C. Aim 3: Assess the efficacy of RBD-foldon as an antigen for sera immunoglobulins, 
examining the correlation between immunoglobulin binding of RBD-foldon and viral 
neutralization. 
For hospitalized positive sera, all samples elicited an endpoint titer dilution of at 
least 1:100. Two samples produced a titer of 1:100, 15 samples produced a titer of 1:300, 
22 samples produced a titer of 1:900, four samples produced a titer of 1:2700, and three 
samples produced a titer of 1:8100 (Figure 14). For non-hospitalized positive sera, two 
samples produced no titer (endpoint dilution <1:100), three samples produced a titer of 
1:100, 18 samples produced a titer of 1:300, 10 samples produced a titer of 1:900, two 
samples produced a titer of 1:8100, and one sample produced a titer of 1:24300 (Figure 
15). Endpoint titers of patients with mild SARS-CoV-2 infection should be lower than 
those with moderate or severe SARS-CoV-2 infection (Ma et al., 2020). 
 
 
FIGURE 14 – RBD-foldon Hospitalized IgG Titers 
 





FIGURE 15 – RBD-foldon Non-Hospitalized IgG Titers  
 
RBD-foldon endpoint titer dilution values were plotted against PRNT50 values. 
PRNT50 is the quantitative value obtained from a Plaque Reduction Neutralization Assay 
and is quantified as the inverse of the highest sera dilution producing 50% viral plaque 
neutralization. Plaque Reduction Neutralization Assays assess sera for neutralizing 
antibodies by measuring the amount of viral plaque neutralization (Timiryasova et al., 
2013). To quantitatively assess correlation of RBD-foldon endpoint titers to PRNT50 
values, linear fit lines were added, and Pearson’s r values were generated. It was 
determined that both non-hospitalized and hospitalized positive endpoint titers were 
positively correlated with PRNT50 values. Non-hospitalized positive endpoint titers 
plotted against PRNT50 produced an r value of 0.5964, or 59.64% (Figure 16A). 
Hospitalized positive endpoint titers plotted against PRNT50 produced an r value of 
0.4869, or 48.69% (Figure 16B).  




The r value produced for non-hospitalized positive samples was higher than the r 
value for hospitalized samples. Overall, PRNT50 values for hospitalized positive sera 
(M=9507.63) were higher than those for non-hospitalized positive sera (M=2101.16). 
Additionally, the standard deviation of PRNT50 values for hospitalized positive sera 
(SD=16705.97) was much greater than that for non-hospitalized positive sera 
(SD=4923.70). This may be due to increased variability of immune response in patients 
with moderate and severe infection (Ma et al., 2020). 
 
 
FIGURE 16 – RBD-foldon IgG Endpoint Titers vs PRNT50 (A) Hospitalized Positive sera titers n=46 vs PRNT50 
Values n=46 (B) Non-Hospitalized Positive sera titers n=21 vs PRNT50 Values n=21 




Out of the 46 hospitalized positive patient sera samples titrated with RBD-foldon, 
18 of them had been titrated with monomeric RBD. Using these 18 positive samples, 
RBD-foldon and RBD endpoint titers were plotted against each other to determine how 
closely they correlated. This produced an r value of 0.9645, indicating that they are 
96.45% correlated (Figure 17A). With an r value of 0.9645, it was presumed that RBD-
foldon endpoint titers should correlate with PRNT50 values at comparable levels to RBD. 
To confirm this, RBD-foldon endpoint titers and RBD endpoint titers were plotted 
against PRNT50 values for the 18 positive samples. The r value produced by RBD-
foldon correlation with PRNT50 was 0.5427, or 54.27% (Figure 17B). The r value 
produced by RBD correlation with PRNT50 was 0.5903, or 59.03% (Figure 17C). 
Predictably, the r values for RBD-foldon and RBD differed by a small margin of 0.0476, 
or 8%. Notably, RBD-foldon endpoint titers (M=1855.56) were overall higher than RBD 
endpoint titers (M=1777.28), suggesting that RBD-foldon may elicit higher levels of 
antibody binding than RBD. The higher r value may indicate that RBD is more predictive 
of protection than RBD-foldon, however, further statistical analysis will be needed to 
determine if there is a significant difference between the r values.  
 





FIGURE 17 – IgG Endpoint Titer Comparison of RBD-foldon and RBD, n=18 (A) RBD-foldon vs RBD Endpoint Titers 

















In the present study, a novel SARS-CoV-2 RBD antigen was developed and 
assessed for SARS-CoV-2 serological detection. Presented in Aim 1, a reproducible 
purification method for plant-expressed RBD-foldon was established. RBD-foldon was 
sufficiently expressed in Nicotiana benthamiana plants using Tobacco Mosaic Virus. 
RBD-foldon was successfully extracted and subsequently purified, then verified on SDS 
PAGE and Western Blotting. After producing multiple lots, they were not statistically 
significant from each other; therefore, RBD-foldon is reproducible. As detailed in Aim 2 
and Aim 3, a serological ELISA was established with RBD-foldon as the target antigen. 
RBD-foldon ELISA absorbances were higher than that for RBD ELISAs, suggesting that 
RBD-foldon exhibited better binding of SARS-CoV-2 RBD-targeting antibodies than 
RBD. Additionally, it was determined that RBD-foldon coated at 5 µg/mL can detect 
SARS-CoV-2 RBD-targeting IgG antibodies with a specificity of 95.65% and sensitivity 
of 90.24%. RBD-foldon binds IgA and IgM antibodies; however, further research using 
samples at uniform infection timepoints would be needed to characterize this response. 
Expectedly, non-hospitalized positive sample RBD-foldon IgG PRNT50 values were 
lower than hospitalized positive sample IgG PRNT50 values. RBD positive sample IgG 
endpoint titers were lower than RBD-foldon positive sample endpoint titers overall 
however, RBD-foldon and RBD were 96.45% correlated. RBD-foldon endpoint titers and 
PRNT50 values were positively correlated, suggesting that RBD-foldon can elicit a 
response from protective RBD-targeting antibodies. As endpoint titers for RBD-foldon 
and RBD are 96.45% correlated, correlation of each with PRNT50 values were similar. 




The r value for RBD correlation with PRNT50 values was 0.5903, while the r for RBD-
foldon correlation with PRNT50 values was 0.5427.  Neither of the r values were 1, due 
to there likely being other binding regions of SARS-CoV-2 protective antibodies besides 
RBD. It was demonstrated that Foldon can be used as a trimerization domain for 
recombinant SARS-CoV-2 RBD. Additionally, it was shown that RBD-foldon can be 
used as strong antigen for serological testing. The findings in this study provide a 
platform for the development of novel viral antigens to aid in the understanding of viral 




















A. Future Improvements 
 RBD-foldon protein purity was characterized using SDS-PAGE and Western 
Blotting. Mass spectrometry of RBD-foldon was not performed; however, it would 
provide deeper insight into the mass-to-charge ratio of RBD-foldon and purity. Mass 
spectrometry would also provide information to determine the identity of the protein 
species seen at 5-10 kD on SDS-PAGE and Western Blots ran in this study. 
 For an FDA Emergency Use Authorization (EUA), antigens used for SARS-CoV-
2 serological tests need to be tested with IgG and/or IgM antibodies specific for the 
endemic coronaviruses responsible for the common cold (alpha-coronaviruses HCoV-
229E, -NL63 and beta-coronaviruses HCoV-OC43, -HKU1), influenza A and B, HCV, 
HBV, HIV, Haemophilus influenzae, and respiratory syncytial virus. The only virus 
targeting antibodies that RBD-foldon was tested with were anti-HIV. Testing with 
potential cross-reactive viruses would need to be done with RBD-foldon to receive an 
emergency use authorization as an antigen for SARS-CoV-2 serologicals. 
 The optimal cutoff absorbance chosen for this RBD-foldon assay was determined 
after testing all sera samples with one lot of RBD-foldon. To make a statistically sound 
decision on the optimal cutoff, testing of all samples in this study would need to be 
repeated with at least two more lots of RBD-foldon. An average optimal cutoff 
absorbance for the assay could be generated using the cutoff value determined for each 
lot.  




 The RBD-foldon produced in this study was shown to be efficacious as an 
antigen, however, there may be structural factors that hinder it from expressing better in 
plants, and performing even better as an antigen, yielding higher optical densities, and 
potentially being more predictive of protection than determined in this study. These 
factors may lie in the signal peptide and/or RBD-to-foldon linker used. The signal peptide 
sequence used can impact the amount of plant expression, while the linker sequence used 
can impact protein stability. As seen in the SDS-PAGE in the results section, there is a 
protein species at 5-10kD. This might be due to instability of the linker, resulting in both 
foldon protein and full-length RBD-foldon protein in the same eluate fractions, as they 
both would bind and elute during metal affinity chromatography due to the his-tag on 
both species.  
B. Future Applications 
 With the emergence of SARS-CoV-2 variants B.1.1.7, B.1.351, and P.1, there is a 
need to characterize existing antibody responses to them. Characterizing antibody 
responses to these variants would allow for epidemiological measures to be taken to track 
and prevent their spread. SARS-CoV-2 variants that have and have yet to emerge may 
have mutations that affect the conformation and function of the Spike protein and RBD, 
potentially increasing infectivity and virulence. Serological testing can determine if 
antibodies to native SARS-CoV-2 are able to recognize variant RBDs. Using foldon to 
make trimeric variant RBD antigens may enhance testing and allow for more robust 
results. 




 Foldon has been shown to be a trimerization domain for production of 
recombinant trimeric viral proteins. This study further supports this and demonstrates an 
example for Foldon fused protein production. Foldon can be fused to trimeric proteins of 
other viruses, producing recombinant trimeric viral proteins that can then be investigated 
in various studies as antigens for vaccines or diagnostics. This study presents a template 
for serology test development using Foldon fused antigens for detection of antibody 
responses to viral proteins. 
 Foldon fused antigens can also be used for vaccine development. It has been 
demonstrated in mice that foldon fused MERS-CoV RBD and foldon fused SARS-CoV 
spike protein can be used to elicit neutralizing antibody titers. This has yet to be 
demonstrated using foldon fused to SARS-CoV-2 RBD or spike protein in a mouse 
model. Therefore RBD-foldon may have efficacy as a vaccine immunogen and 
investigating the immunogenic potential of the plant-made RBD-foldon discussed in this 

























1 Hospitalized 1.54033 0.20517 1.62175 300 836.40623 
2 Hospitalized 0.74583 0.31517 2.85825 900 921.62114 
3 Hospitalized 0.67783 0.34317 0.47925 100 <256 
4 Hospitalized 0.99933 0.27067 1.52375 300 258.98954 
5 Hospitalized 0.62183 0.22717 1.70475 900 1313.68166 
6 Hospitalized 0.68583 0.28917 1.06425 300 449.10221 
7 Hospitalized 0.78883 0.17217 0.71725 300 480.18948 
8 Hospitalized 0.88683 0.47967 0.71125 900 573.74664 
9 Hospitalized 1.61183 0.36017 2.57075 300 8476.12680 
10 Hospitalized 1.37233 0.43717 1.83525 900 1338.03487 
11 Hospitalized 0.45933 0.10267 1.05375 100 280.18774 
12 Hospitalized 2.73683 0.87467 1.89875 900 40379.72907 
13 Hospitalized 0.71533 0.33567 1.53775 900 4765.13047 
14 Hospitalized 0.78783 0.53117 1.42475 300 853.79742 
15 Hospitalized 2.11933 0.66317 2.15475 900 4224.60283 
16 Hospitalized 0.34633 0.20417 1.87675 2700 1844.73772 
17 Hospitalized 0.51233 0.44967 2.22425 900 1145.53038 
18 Hospitalized 0.44583 1.25017 2.38525 900 1213.15711 
19 Hospitalized 0.45033 0.19517 0.86775 300 430.68223 
20 Hospitalized 0.72133 0.13167 2.88325 8100 26949.80005 
21 Hospitalized 1.73183 0.65817 1.37975 900 26866.56566 
22 Hospitalized 0.54533 0.15967 0.83125 900 673.83894 
23 Hospitalized 0.73033 0.21467 1.06225 300 819.57377 
24 Hospitalized 1.12433 0.12850 0.90950 300 312.85492 




25 Hospitalized 1.81983 0.36550 2.12800 900 231.55482 
26 Hospitalized 1.27933 0.36850 1.15700 900 4746.34087 
27 Hospitalized 0.37933 0.20000 0.84050 300 1077.22209 
28 Hospitalized 0.62183 0.13450 1.58950 900 1048.74972 
29 Hospitalized 0.58283 0.15100 0.90850 300 576.34945 
30 Hospitalized 0.29483 0.27350 1.15950 900 274.88607 
31 Hospitalized 0.76933 0.42750 1.45700 900 16268.57199 
32 Hospitalized 0.99133 0.86100 1.79950 2700 4185.25555 
33 Hospitalized 0.78633 1.00400 1.97900 2700 9812.41159 
34 Hospitalized 1.25383 0.20550 1.59100 900 3625.58982 
35 Hospitalized 0.91933 0.23150 1.61700 900 52226.84076 
36 Hospitalized 1.02883 0.58600 0.98450 300 6135.64799 
37 Hospitalized 0.67833 0.62600 1.39550 300 2531.97299 
38 Hospitalized 2.46533 0.78300 1.50200 2700 37905.38126 
39 Hospitalized 0.44283 0.35050 1.58050 900 2326.58793 
40 Hospitalized 0.57633 0.39300 1.34600 900 8327.10904 
41 Hospitalized 0.52483 0.51450 1.19100 300 348.02328 
42 Hospitalized 1.62183 0.53500 1.46400 900 71725.57459 
43 Hospitalized 1.10733 0.83700 2.09450 8100 49766.67608 
44 Hospitalized 0.32883 0.05900 0.88100 300 2895.30577 
45 Hospitalized 1.01783 0.26150 1.59950 900 1562.99776 
46 Hospitalized 2.49483 0.85050 2.09500 8100 34344.03843 
47 Non-Hospitalized 1.03200 0.42150 1.26900 300 <256 
48 Non-Hospitalized 0.71550 2.24600 2.75000 8100 2626.41000 
49 Non-Hospitalized 0.72300 0.56650 2.69050 8100 19542.41000 
50 Non-Hospitalized 1.15900 0.33300 0.80950 300 1584.83000 
51 Non-Hospitalized 1.31250 0.59550 2.13550 900 <256 
52 Non-Hospitalized 0.34550 0.28500 1.51900 900 351.30000 




53 Non-Hospitalized 0.71500 0.14950 1.02700 300 615.55000 
54 Non-Hospitalized 0.50800 -0.02700 1.12200 300 346.07000 
55 Non-Hospitalized 0.93750 0.44700 1.72650 900 379.42603 
56 Non-Hospitalized 2.20650 0.27450 1.59600 300 101.75949 
57 Non-Hospitalized 0.41100 0.58100 1.80150 900 1584.97230 
58 Non-Hospitalized 0.20900 1.57050 0.98150 300 780.43602 
59 Non-Hospitalized 0.14800 0.07250 0.90950 300 <256 
60 Non-Hospitalized 1.26400 1.24950 1.74400 900 1226.90420 
61 Non-Hospitalized 0.55650 0.15600 1.04600 300 <256 
62 Non-Hospitalized 2.30250 0.31550 1.62900 900 946.81037 
63 Non-Hospitalized 0.47300 0.14550 0.73350 100 <256 
64 Non-Hospitalized 1.22950 0.18300 0.42800 100 <256 
65 Non-Hospitalized 0.94050 0.28350 1.13600 300 13399.51000 
66 Non-Hospitalized 0.63950 0.36500 0.92400 300 <256 
67 Non-Hospitalized 0.66650 0.20850 0.99800 300 637.86000 
68 Non-Hospitalized 0.88700 0.10400 0.81700 300 Not Tested 
69 Non-Hospitalized 0.36950 0.18350 0.35000 <100 Not Tested 
70 Non-Hospitalized 1.04550 0.10200 0.95450 300 Not Tested 
71 Non-Hospitalized 0.33050 0.53750 0.47550 100 Not Tested 
72 Non-Hospitalized 0.78850 0.17550 1.42300 900 Not Tested 
73 Non-Hospitalized 0.55600 0.18650 1.46750 900 Not Tested 
74 Non-Hospitalized 0.98800 0.41750 2.46150 24300 Not Tested 
75 Non-Hospitalized 0.23250 0.20950 1.15950 300 Not Tested 
76 Non-Hospitalized 0.34000 0.54300 1.55850 900 Not Tested 
77 Non-Hospitalized 0.56050 0.22650 0.78700 300 Not Tested 
78 Non-Hospitalized 0.39300 0.25300 0.29850 <100 Not Tested 
79 Non-Hospitalized 0.27000 0.09250 1.46250 900 Not Tested 
80 Non-Hospitalized 1.36550 0.46000 1.00800 300 Not Tested 




81 Non-Hospitalized 0.19700 0.28450 0.88300 300 Not Tested 
82 Non-Hospitalized 0.44050 0.18850 1.19200 300 Not Tested 
83 Negative 0.13183 0.38567 0.29275 Not Tested Not Tested 
84 Negative 0.16583 0.08667 0.09925 Not Tested Not Tested 
85 Negative 0.19833 0.40217 0.19675 Not Tested Not Tested 
86 Negative 0.12883 0.11017 0.14875 Not Tested Not Tested 
87 Negative 1.19033 0.22567 0.30975 Not Tested Not Tested 
88 Negative 0.04583 0.28267 0.17225 Not Tested Not Tested 
89 Negative 0.23733 0.21867 0.13725 Not Tested Not Tested 
90 Negative 0.41783 0.17917 0.09575 Not Tested Not Tested 
91 Negative 0.17633 0.14067 0.30875 Not Tested Not Tested 
92 Negative 0.19883 0.08117 0.27025 Not Tested Not Tested 
93 Negative 0.22933 0.19067 0.15075 Not Tested Not Tested 
94 Negative 0.14783 0.25117 0.12475 Not Tested Not Tested 
95 Negative 0.14533 0.04817 0.20325 Not Tested Not Tested 
96 Negative 1.06383 0.17917 0.58075 Not Tested Not Tested 
97 Negative 0.62333 0.13267 0.12725 Not Tested Not Tested 
98 Negative 0.85683 0.07167 0.08875 Not Tested Not Tested 
99 Negative 1.59583 0.23267 0.36775 Not Tested Not Tested 
100 Negative 0.20833 0.03267 0.10375 Not Tested Not Tested 
101 Negative 0.26733 0.15717 0.14475 Not Tested Not Tested 
102 Negative 0.93983 0.20517 0.31475 Not Tested Not Tested 
103 Negative 0.17983 0.22367 0.14725 Not Tested Not Tested 
104 Negative 0.53533 0.29917 0.17825 Not Tested Not Tested 
105 Negative 0.42133 0.17467 0.25475 Not Tested Not Tested 
106 Negative 0.28533 0.10450 0.78600 Not Tested Not Tested 
107 Negative 0.96483 0.13000 0.31050 Not Tested Not Tested 
108 Negative 0.53783 0.14100 0.32150 Not Tested Not Tested 




109 Negative 0.52733 0.09200 0.29250 Not Tested Not Tested 
110 Negative 0.16433 0.20400 0.71650 Not Tested Not Tested 
111 Negative 0.06533 0.14350 0.22950 Not Tested Not Tested 
112 Negative 0.11133 0.22650 1.02250 Not Tested Not Tested 
113 Negative 0.09133 0.18500 0.23100 Not Tested Not Tested 
114 Negative 0.34233 0.18650 0.26050 Not Tested Not Tested 
115 Negative 0.43583 0.23450 0.19750 Not Tested Not Tested 
116 Negative 0.03783 -0.02150 0.27550 Not Tested Not Tested 
117 Negative 0.16133 0.06500 0.26200 Not Tested Not Tested 
118 Negative 0.10533 0.12150 0.29450 Not Tested Not Tested 
119 Negative 0.26833 0.23950 1.17150 Not Tested Not Tested 
120 Negative 0.17083 0.26950 0.49150 Not Tested Not Tested 
121 Negative 0.26633 0.46150 0.73500 Not Tested Not Tested 
122 Negative 0.16833 0.11200 0.30700 Not Tested Not Tested 
123 Negative 0.49683 0.39250 0.50100 Not Tested Not Tested 
124 Negative 0.40983 0.17700 0.26200 Not Tested Not Tested 
125 Negative 0.26183 0.05500 0.19250 Not Tested Not Tested 
126 Negative 0.09433 0.12500 0.64550 Not Tested Not Tested 
127 Negative 1.36483 0.99450 0.76650 Not Tested Not Tested 












APPENDIX II – ROC CURVE DATA 
A. IgG Pivot Table with Sensitivity, Specificity, and False Positive Rate 
Optical Density (AU) Diseased (Pos) Healthy (Neg) Sensitivity Specificity False Positive Rate 
0.08875  1 1 0 1 
0.09575  1 1 0.0217391 0.97826087 
0.09925  1 1 0.0434783 0.956521739 
0.10375  1 1 0.0652174 0.934782609 
0.12475  1 1 0.0869565 0.913043478 
0.12725  1 1 0.1086957 0.891304348 
0.13725  1 1 0.1304348 0.869565217 
0.14475  1 1 0.1521739 0.847826087 
0.14725  1 1 0.173913 0.826086957 
0.14875  1 1 0.1956522 0.804347826 
0.15075  1 1 0.2173913 0.782608696 
0.17225  1 1 0.2391304 0.760869565 
0.17825  1 1 0.2608696 0.739130435 
0.1925  1 1 0.2826087 0.717391304 
0.19675  1 1 0.3043478 0.695652174 
0.1975  1 1 0.326087 0.673913043 
0.20325  1 1 0.3478261 0.652173913 
0.2295  1 1 0.3695652 0.630434783 
0.231  1 1 0.3913043 0.608695652 
0.247  1 1 0.4130435 0.586956522 
0.25475  1 1 0.4347826 0.565217391 
0.2605  1 1 0.4565217 0.543478261 
0.262  2 1 0.4782609 0.52173913 
0.27025  1 1 0.5217391 0.47826087 
0.2755  1 1 0.5434783 0.456521739 




0.2925  1 1 0.5652174 0.434782609 
0.29275  1 1 0.5869565 0.413043478 
0.2945  1 1 0.6086957 0.391304348 
0.2985 1  1 0.6304348 0.369565217 
0.307  1 0.98780488 0.6304348 0.369565217 
0.30875  1 0.98780488 0.6521739 0.347826087 
0.30975  1 0.98780488 0.673913 0.326086957 
0.3105  1 0.98780488 0.6956522 0.304347826 
0.31475  1 0.98780488 0.7173913 0.282608696 
0.3215  1 0.98780488 0.7391304 0.260869565 
0.35 1  0.98780488 0.7608696 0.239130435 
0.36775  1 0.97560976 0.7608696 0.239130435 
0.428 1  0.97560976 0.7826087 0.217391304 
0.4755 1  0.96341463 0.7826087 0.217391304 
0.47925 1  0.95121951 0.7826087 0.217391304 
0.4915  1 0.93902439 0.7826087 0.217391304 
0.501  1 0.93902439 0.8043478 0.195652174 
0.58075  1 0.93902439 0.826087 0.173913043 
0.6455  1 0.93902439 0.8478261 0.152173913 
0.71125 1  0.93902439 0.8695652 0.130434783 
0.7165  1 0.92682927 0.8695652 0.130434783 
0.71725 1  0.92682927 0.8913043 0.108695652 
0.7335 1  0.91463415 0.8913043 0.108695652 
0.735  1 0.90243902 0.8913043 0.108695652 
0.7665  1 0.90243902 0.9130435 0.086956522 
0.786  1 0.90243902 0.9347826 0.065217391 
0.787 1  0.90243902 0.9565217 0.043478261 
0.8095 1  0.8902439 0.9565217 0.043478261 




0.817 1  0.87804878 0.9565217 0.043478261 
0.83125 1  0.86585366 0.9565217 0.043478261 
0.8405 1  0.85365854 0.9565217 0.043478261 
0.86775 1  0.84146341 0.9565217 0.043478261 
0.881 1  0.82926829 0.9565217 0.043478261 
0.883 1  0.81707317 0.9565217 0.043478261 
0.9085 1  0.80487805 0.9565217 0.043478261 
0.9095 2  0.79268293 0.9565217 0.043478261 
0.924 1  0.76829268 0.9565217 0.043478261 
0.9545 1  0.75609756 0.9565217 0.043478261 
0.9815 1  0.74390244 0.9565217 0.043478261 
0.9845 1  0.73170732 0.9565217 0.043478261 
0.998 1  0.7195122 0.9565217 0.043478261 
1.008 1  0.70731707 0.9565217 0.043478261 
1.0225  1 0.69512195 0.9565217 0.043478261 
1.027 1  0.69512195 0.9782609 0.02173913 
1.046 1  0.68292683 0.9782609 0.02173913 
1.05375 1  0.67073171 0.9782609 0.02173913 
1.06225 1  0.65853659 0.9782609 0.02173913 
1.06425 1  0.64634146 0.9782609 0.02173913 
1.122 1  0.63414634 0.9782609 0.02173913 
1.136 1  0.62195122 0.9782609 0.02173913 
1.157 1  0.6097561 0.9782609 0.02173913 
1.1595 2  0.59756098 0.9782609 0.02173913 
1.1715  1 0.57317073 0.9782609 0.02173913 
1.191 1  0.57317073 1 0 
1.192 1  0.56097561 1 0 
1.269 1  0.54878049 1 0 




1.346 1  0.53658537 1 0 
1.37975 1  0.52439024 1 0 
1.3955 1  0.51219512 1 0 
1.423 1  0.5 1 0 
1.42475 1  0.48780488 1 0 
1.457 1  0.47560976 1 0 
1.4625 1  0.46341463 1 0 
1.464 1  0.45121951 1 0 
1.4675 1  0.43902439 1 0 
1.502 1  0.42682927 1 0 
1.519 1  0.41463415 1 0 
1.52375 1  0.40243902 1 0 
1.53775 1  0.3902439 1 0 
1.5585 1  0.37804878 1 0 
1.5805 1  0.36585366 1 0 
1.5895 1  0.35365854 1 0 
1.591 1  0.34146341 1 0 
1.596 1  0.32926829 1 0 
1.5995 1  0.31707317 1 0 
1.617 1  0.30487805 1 0 
1.62175 1  0.29268293 1 0 
1.629 1  0.2804878 1 0 
1.70475 1  0.26829268 1 0 
1.7265 1  0.25609756 1 0 
1.744 1  0.24390244 1 0 
1.7995 1  0.23170732 1 0 
1.8015 1  0.2195122 1 0 
1.83525 1  0.20731707 1 0 




1.87675 1  0.19512195 1 0 
1.89875 1  0.18292683 1 0 
1.979 1  0.17073171 1 0 
2.0945 1  0.15853659 1 0 
2.095 1  0.14634146 1 0 
2.128 1  0.13414634 1 0 
2.1355 1  0.12195122 1 0 
2.15475 1  0.1097561 1 0 
2.22425 1  0.09756098 1 0 
2.38525 1  0.08536585 1 0 
2.4615 1  0.07317073 1 0 
2.57075 1  0.06097561 1 0 
2.6905 1  0.04878049 1 0 
2.75 1  0.03658537 1 0 
2.85825 1  0.02439024 1 0 
2.88325 1  0.01219512 1 0 
Grand Total 82 46    
 
B. IgA Pivot Table with Sensitivity, Specificity, and False Positive Rate 
Optical Density (AU) Diseased (Pos) Healthy (Neg) Sensitivity Specificity False Positive Rate 
-0.027 1 
 
1 0 1 
-0.0215 
 
1 0.98780488 0 1 
0.032666667 
 
1 0.98780488 0.0217391 0.97826087 
0.048166667 
 
1 0.98780488 0.0434783 0.956521739 
0.055 
 
1 0.98780488 0.0652174 0.934782609 
0.059 1 
 
0.98780488 0.0869565 0.913043478 
0.065 
 
1 0.97560976 0.0869565 0.913043478 
0.071666667 
 
1 0.97560976 0.1086957 0.891304348 






0.97560976 0.1304348 0.869565217 
0.081166667 
 
1 0.96341463 0.1304348 0.869565217 
0.086666667 
 
1 0.96341463 0.1521739 0.847826087 
0.092 
 
1 0.96341463 0.173913 0.826086957 
0.0925 1 
 
0.96341463 0.1956522 0.804347826 
0.102 1 
 
0.95121951 0.1956522 0.804347826 
0.102666667 1 
 
0.93902439 0.1956522 0.804347826 
0.104 1 
 
0.92682927 0.1956522 0.804347826 
0.1045 
 
1 0.91463415 0.1956522 0.804347826 
0.110166667 
 
1 0.91463415 0.2173913 0.782608696 
0.112 
 
1 0.91463415 0.2391304 0.760869565 
0.1215 
 
1 0.91463415 0.2608696 0.739130435 
0.125 
 
1 0.91463415 0.2826087 0.717391304 
0.1285 1 
 
0.91463415 0.3043478 0.695652174 
0.13 
 
1 0.90243902 0.3043478 0.695652174 
0.131666667 1 
 
0.90243902 0.326087 0.673913043 
0.132666667 
 
1 0.8902439 0.326087 0.673913043 
0.1345 1 
 
0.8902439 0.3478261 0.652173913 
0.140666667 
 
1 0.87804878 0.3478261 0.652173913 
0.141 
 
1 0.87804878 0.3695652 0.630434783 
0.1435 
 
1 0.87804878 0.3913043 0.608695652 
0.1455 1 
 
0.87804878 0.4130435 0.586956522 
0.1495 1 
 
0.86585366 0.4130435 0.586956522 
0.151 1 
 
0.85365854 0.4130435 0.586956522 
0.156 1 
 
0.84146341 0.4130435 0.586956522 
0.157166667 
 
1 0.82926829 0.4130435 0.586956522 
0.159666667 1 
 
0.82926829 0.4347826 0.565217391 
0.172166667 1 
 
0.81707317 0.4347826 0.565217391 






1 0.80487805 0.4347826 0.565217391 
0.1755 1 
 
0.80487805 0.4565217 0.543478261 
0.177 
 
1 0.79268293 0.4565217 0.543478261 
0.179166667 
 
2 0.79268293 0.4782609 0.52173913 
0.183 1 
 
0.79268293 0.5217391 0.47826087 
0.1835 1 
 
0.7804878 0.5217391 0.47826087 
0.185 
 
1 0.76829268 0.5217391 0.47826087 
0.1865 1 1 0.76829268 0.5434783 0.456521739 
0.1885 1 
 
0.75609756 0.5652174 0.434782609 
0.190666667 
 
1 0.74390244 0.5652174 0.434782609 
0.195166667 1 
 
0.74390244 0.5869565 0.413043478 
0.2 1 
 
0.73170732 0.5869565 0.413043478 
0.204 
 
1 0.7195122 0.5869565 0.413043478 
0.204166667 1 
 
0.7195122 0.6086957 0.391304348 
0.205166667 1 
 
0.70731707 0.6086957 0.391304348 
0.205166667 
 
1 0.69512195 0.6086957 0.391304348 
0.2055 1 
 
0.69512195 0.6304348 0.369565217 
0.2085 1 
 
0.68292683 0.6304348 0.369565217 
0.2095 1 
 
0.67073171 0.6304348 0.369565217 
0.214666667 1 
 
0.65853659 0.6304348 0.369565217 
0.218666667 
 
1 0.64634146 0.6304348 0.369565217 
0.223666667 
 
1 0.64634146 0.6521739 0.347826087 
0.225666667 
 
1 0.64634146 0.673913 0.326086957 
0.2265 
 
1 0.64634146 0.6956522 0.304347826 
0.2265 1 
 
0.64634146 0.7173913 0.282608696 
0.227166667 1 
 
0.63414634 0.7173913 0.282608696 
0.2315 1 
 
0.62195122 0.7173913 0.282608696 
0.232666667 
 
1 0.6097561 0.7173913 0.282608696 






1 0.6097561 0.7391304 0.260869565 
0.2395 
 
1 0.6097561 0.7608696 0.239130435 
0.251166667 
 
1 0.6097561 0.7826087 0.217391304 
0.253 1 
 
0.6097561 0.8043478 0.195652174 
0.2615 1 
 
0.59756098 0.8043478 0.195652174 
0.2695 
 
1 0.58536585 0.8043478 0.195652174 
0.270666667 1 
 
0.58536585 0.826087 0.173913043 
0.2735 1 
 
0.57317073 0.826087 0.173913043 
0.2745 1 
 
0.56097561 0.826087 0.173913043 
0.282666667 
 
1 0.54878049 0.826087 0.173913043 
0.2835 1 
 
0.54878049 0.8478261 0.152173913 
0.2845 1 
 
0.53658537 0.8478261 0.152173913 
0.285 1 
 
0.52439024 0.8478261 0.152173913 
0.289166667 1 
 
0.51219512 0.8478261 0.152173913 
0.291 
 
1 0.5 0.8478261 0.152173913 
0.299166667 
 
1 0.5 0.8695652 0.130434783 
0.315166667 1 
 
0.5 0.8913043 0.108695652 
0.3155 1 
 
0.48780488 0.8913043 0.108695652 
0.333 1 
 
0.47560976 0.8913043 0.108695652 
0.335666667 1 
 
0.46341463 0.8913043 0.108695652 
0.343166667 1 
 
0.45121951 0.8913043 0.108695652 
0.3505 1 
 
0.43902439 0.8913043 0.108695652 
0.360166667 1 
 
0.42682927 0.8913043 0.108695652 
0.365 1 
 
0.41463415 0.8913043 0.108695652 
0.3655 1 
 
0.40243902 0.8913043 0.108695652 
0.3685 1 
 
0.3902439 0.8913043 0.108695652 
0.385666667 
 
1 0.37804878 0.8913043 0.108695652 
0.3925 
 
1 0.37804878 0.9130435 0.086956522 






0.37804878 0.9347826 0.065217391 
0.402166667 
 
1 0.36585366 0.9347826 0.065217391 
0.4175 1 
 
0.36585366 0.9565217 0.043478261 
0.4215 1 
 
0.35365854 0.9565217 0.043478261 
0.4275 1 
 
0.34146341 0.9565217 0.043478261 
0.437166667 1 
 
0.32926829 0.9565217 0.043478261 
0.447 1 
 
0.31707317 0.9565217 0.043478261 
0.449666667 1 
 
0.30487805 0.9565217 0.043478261 
0.46 1 
 
0.29268293 0.9565217 0.043478261 
0.4615 
 
1 0.2804878 0.9565217 0.043478261 
0.479666667 1 
 
0.2804878 0.9782609 0.02173913 
0.5145 1 
 
0.26829268 0.9782609 0.02173913 
0.531166667 1 
 
0.25609756 0.9782609 0.02173913 
0.535 1 
 
0.24390244 0.9782609 0.02173913 
0.5375 1 
 
0.23170732 0.9782609 0.02173913 
0.543 1 
 
0.2195122 0.9782609 0.02173913 
0.5665 1 
 
0.20731707 0.9782609 0.02173913 
0.581 1 
 
0.19512195 0.9782609 0.02173913 
0.586 1 
 
0.18292683 0.9782609 0.02173913 
0.5955 1 
 
0.17073171 0.9782609 0.02173913 
0.626 1 
 
0.15853659 0.9782609 0.02173913 
0.658166667 1 
 
0.14634146 0.9782609 0.02173913 
0.663166667 1 
 
0.13414634 0.9782609 0.02173913 
0.783 1 
 
0.12195122 0.9782609 0.02173913 
0.837 1 
 
0.1097561 0.9782609 0.02173913 
0.8505 1 
 
0.09756098 0.9782609 0.02173913 
0.861 1 
 
0.08536585 0.9782609 0.02173913 
0.874666667 1 
 
0.07317073 0.9782609 0.02173913 






1 0.06097561 0.9782609 0.02173913 
1.004 1 
 
0.06097561 1 0 
1.2495 1 
 
0.04878049 1 0 
1.250166667 1 
 
0.03658537 1 0 
1.5705 1 
 
0.02439024 1 0 
2.246 1 
 
0.01219512 1 0 
Grand Total 82 46    
 
C. IgM Pivot Table with Sensitivity, Specificity, and False Positive Rate 
Optical Density (AU) Diseased (Pos) Healthy (Neg) Sensitivity Specificity False Positive Rate 
0.037833333 
 
1 1 0 1 
0.045833333 
 
1 1 0.0217391 0.97826087 
0.065333333 
 
1 1 0.0434783 0.956521739 
0.091333333 
 
1 1 0.0652174 0.934782609 
0.094333333 
 
1 1 0.0869565 0.913043478 
0.105333333 
 
1 1 0.1086957 0.891304348 
0.111333333 
 
1 1 0.1304348 0.869565217 
0.114333333 
 
1 1 0.1521739 0.847826087 
0.128833333 
 
1 1 0.173913 0.826086957 
0.131833333 
 
1 1 0.1956522 0.804347826 
0.145333333 
 
1 1 0.2173913 0.782608696 
0.147833333 
 
1 1 0.2391304 0.760869565 
0.148 1 
 
1 0.2608696 0.739130435 
0.161333333 
 
1 0.98780488 0.2608696 0.739130435 
0.164333333 
 
1 0.98780488 0.2826087 0.717391304 
0.165833333 
 
1 0.98780488 0.3043478 0.695652174 
0.168333333 
 
1 0.98780488 0.326087 0.673913043 
0.170833333 
 
1 0.98780488 0.3478261 0.652173913 






1 0.98780488 0.3695652 0.630434783 
0.179833333 
 
1 0.98780488 0.3913043 0.608695652 
0.197 1 
 
0.98780488 0.4130435 0.586956522 
0.198333333 
 
1 0.97560976 0.4130435 0.586956522 
0.198833333 
 
1 0.97560976 0.4347826 0.565217391 
0.208333333 
 
1 0.97560976 0.4565217 0.543478261 
0.209 1 
 
0.97560976 0.4782609 0.52173913 
0.229333333 
 
1 0.96341463 0.4782609 0.52173913 
0.2325 1 
 
0.96341463 0.5 0.5 
0.237333333 
 
1 0.95121951 0.5 0.5 
0.261833333 
 
1 0.95121951 0.5217391 0.47826087 
0.266333333 
 
1 0.95121951 0.5434783 0.456521739 
0.267333333 
 
1 0.95121951 0.5652174 0.434782609 
0.268333333 
 
1 0.95121951 0.5869565 0.413043478 
0.27 1 
 
0.95121951 0.6086957 0.391304348 
0.285333333 
 
1 0.93902439 0.6086957 0.391304348 
0.294833333 1 
 
0.93902439 0.6304348 0.369565217 
0.328833333 1 
 
0.92682927 0.6304348 0.369565217 
0.3305 1 
 
0.91463415 0.6304348 0.369565217 
0.34 1 
 
0.90243902 0.6304348 0.369565217 
0.342333333 
 
1 0.8902439 0.6304348 0.369565217 
0.3455 1 
 
0.8902439 0.6521739 0.347826087 
0.346333333 1 
 
0.87804878 0.6521739 0.347826087 
0.3695 1 
 
0.86585366 0.6521739 0.347826087 
0.379333333 1 
 
0.85365854 0.6521739 0.347826087 
0.393 1 
 
0.84146341 0.6521739 0.347826087 
0.409833333 
 
1 0.82926829 0.6521739 0.347826087 
0.411 1 
 
0.82926829 0.673913 0.326086957 






1 0.81707317 0.673913 0.326086957 
0.421333333 
 
1 0.81707317 0.6956522 0.304347826 
0.435833333 
 
1 0.81707317 0.7173913 0.282608696 
0.4405 1 
 
0.81707317 0.7391304 0.260869565 
0.442833333 1 
 
0.80487805 0.7391304 0.260869565 
0.445833333 1 
 
0.79268293 0.7391304 0.260869565 
0.450333333 1 
 
0.7804878 0.7391304 0.260869565 
0.459333333 1 
 
0.76829268 0.7391304 0.260869565 
0.473 1 
 
0.75609756 0.7391304 0.260869565 
0.496833333 
 
1 0.74390244 0.7391304 0.260869565 
0.508 1 
 
0.74390244 0.7608696 0.239130435 
0.512333333 1 
 
0.73170732 0.7608696 0.239130435 
0.524833333 1 
 
0.7195122 0.7608696 0.239130435 
0.527333333 
 
1 0.70731707 0.7608696 0.239130435 
0.535333333 
 
1 0.70731707 0.7826087 0.217391304 
0.537833333 
 
1 0.70731707 0.8043478 0.195652174 
0.545333333 1 
 
0.70731707 0.826087 0.173913043 
0.556 1 
 
0.69512195 0.826087 0.173913043 
0.5565 1 
 
0.68292683 0.826087 0.173913043 
0.5605 1 
 
0.67073171 0.826087 0.173913043 
0.576333333 1 
 
0.65853659 0.826087 0.173913043 
0.582833333 1 
 
0.64634146 0.826087 0.173913043 
0.621833333 2 
 
0.63414634 0.826087 0.173913043 
0.623333333 
 
1 0.6097561 0.826087 0.173913043 
0.6395 1 
 
0.6097561 0.8478261 0.152173913 
0.6665 1 
 
0.59756098 0.8478261 0.152173913 
0.677833333 1 
 
0.58536585 0.8478261 0.152173913 
0.678333333 1 
 
0.57317073 0.8478261 0.152173913 






0.56097561 0.8478261 0.152173913 
0.715 1 
 
0.54878049 0.8478261 0.152173913 
0.715333333 1 
 
0.53658537 0.8478261 0.152173913 
0.7155 1 
 
0.52439024 0.8478261 0.152173913 
0.721333333 1 
 
0.51219512 0.8478261 0.152173913 
0.723 1 
 
0.5 0.8478261 0.152173913 
0.730333333 1 
 
0.48780488 0.8478261 0.152173913 
0.745833333 1 
 
0.47560976 0.8478261 0.152173913 
0.769333333 1 
 
0.46341463 0.8478261 0.152173913 
0.786333333 1 
 
0.45121951 0.8478261 0.152173913 
0.787833333 1 
 
0.43902439 0.8478261 0.152173913 
0.7885 1 
 
0.42682927 0.8478261 0.152173913 
0.788833333 1 
 
0.41463415 0.8478261 0.152173913 
0.856833333 
 
1 0.40243902 0.8478261 0.152173913 
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